Development and Characterization of Lamivudine Loaded Nanoparticles. by Palanikumar, S
DEVELOPMENT
LAMIVUDINE LOADED NANOPARTICLES
Dissertation submitted in partial fulfillment of the requirement for the award of the 
THE TAMILNADU Dr.
DEPARTMENT OF PHARMACEUTICS
K.M.COLLEGE OF PHARMACY
UTHANGUDI, MADURAI
 
 AND CHARACTERIZATION
 
Degree of 
MASTER OF PHARMACY 
IN 
PHARMACEUTICS 
 M.G.R. MEDICAL UNIVERSITY,
CHENNAI 
 
 
 
 
 
 - 625 107 
 
APRIL – 2012 
 
 OF 
 
 
CERTIFICATE 
 
This is to Certify that the dissertation entitled “DEVELOPMENT AND 
CHARACTERIZATION OF LAMIVUDINE LOADED NANOPARTICLES” 
submitted by Mr.S.PALANIKUMAR to Tamilnadu Dr.M.G.R.Medical University, 
Chennai, in Partial fulfillment for the award of Master of Pharmacy in Pharmaceutics 
at K.M. College of Pharmacy, Madurai, is a bonafide work carried out by him under 
my guidance and supervision during the academic year 2011-2012. 
 
 
 
 
 
 
      PRINCIPAL & GUIDE 
                                                                                 
 Dr. S. JAYAPRAKASH, M.Pharm, Ph.D.,  
      Prof & HOD Dept. of Pharmaceutics,  
      K.M.College of Pharmacy,                                               
      Uthangudi, Madurai-625107,           
      Tamilnadu.                                                                        
               , 
 
 
 
 
 
 
 
 
 
 
 
  
DEDICATED TO MY 
FATHER AND MOTHER 
 
 
 
                                      
 
 
ACKNOWLEDEMENT 
It affords me immense pleasure to acknowledge with gratitude the help and 
guidance rendered to me by a host of people, to whom I owe a substantial measure 
for the successful complements of this project. 
I owe my great debt of gratitude and heartful thanks to Prof. M.Nagarajan, 
M. Pharm, M.B.A, DMS (IM) DMS  (BM) Correspondent, K. M. College of 
Pharmacy, Madurai for providing me with all the  facilities and encouragement for 
the successful completion of my thesis work. 
I express my wholehearted gratitude to my esteemed teacher and guide, 
Dr.S.Jayaprakash, M. Pharm, Ph.D, Principal and H.O.D., Dept. of pharmaceutics 
for his zealous guidance, indefatigable support and constant encouragement for the 
entire period of thesis work. 
I prevail my sense of gradtitude to, Mr. S.Mohamed Halith, M.Pharm, 
(Ph.D), & Mr. K. K. Pillai M.Pharm, (Ph.D), Asst.Professor, Dept. of 
Pharmaceutics, for their invaluable advice, suggestion and encouragement extended 
throughout the work. 
          I would like to express my profound sense of gratitude to Mr. Boopathi, 
Asst.prof, Mr. Chidambaranathan, Asst.prof, and all other staffs for their valuable 
suggestions and help thought out this work. 
         I sincerely thank Mrs.Ayyammal, Lab assistants and Mrs.Shanmugapriya, 
store in charge for their gracious renderable help during my project work. 
        I express my gratitude to my friends Karthik, Ebin, and all my juniors Sahul, 
Suthakar who helped me directly and indirectly for the successful completion of my 
project work.  
       I would not be completed if I do not convey my heartful thanks to my parents 
for their encouragement and moral support not only during my course but also 
throughout my life. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
            
 
 
 
 
  
 
 
CONTENTS 
S.NO CHAPTERS PAGE.NO 
1. INTROTUCTION 1 
1.1. Carriers of Targeted Drug Delivery System 2 
1.2. Levels of Drug Targeting 3 
1.3. Particulate/Colloidal Drug carrier system 7 
1.4. Polymeric Nanoparticles 11 
1.5. Preparation Techniques of Nanoparticles 14 
1.6. Purification of Nanoparticle 18 
1.7. Freeze Drying 19 
1.8. Sterilization 20 
1.9. Evaluation of Nanoparticles 21 
1.10. Applications of Nanoparticles 24 
1.11. Introduction about HIV 25 
2. LITERATURE OF REVIEW 28 
3. AIM OF WORK 49 
4. PLAN OF WORK 50 
5. METHODOLOGY 51 
5.1 Instrument and material used  52 
5.2 Drug Profile 53 
5.3 Carrier Profile 57 
6. EXPERIMENTAL INVESTIGATIONS 62 
6.1 Construction of Standard Curve for Lamivudine 62 
6.2 Pre-Formulation Study 64 
6.3 Method of preparation of Lamivudine 
nanoparticle 
66 
6.4 Evaluation of nanoparticles 67 
 
6.4.1  Drug entrapment study 67 
S.NO CHAPTERS PAGE.NO 
 6.4.2 In vitro drug releases 68 
 6.4.3 Morphology of nanoparticles by 
microscopy 
68 
 6.4.4 Scanning electron microscopy 68 
 6.4.5 Surface charge (Zeta potential) determination 
68 
 
6.4.6 pH and physical appearance 68 
 
6.4.7 Sterility testing of nanoparticles 69 
 
6.4.8 Stability studies of nanoparticles 70 
7. RESULTS AND DISCUSSION 72 
8. CONCLUSION 103 
9. BIBILIOGRAPHY   
 
                                  
INTRODUCTION 
 
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai. 1 
 
1. INTRODUCTION 
Most of the drugs introduced to clinical medicine exert their effects by 
interactive interference with cell and cell membrane related structure and functions 
through concentration dependent reversible interactions at specific receptor site(s).  
Obviously, to obtain a desirable therapeutic response, the correct amount of drug 
should be transported and delivered to the site of action with subsequent control of 
drug input rate. The distribution of other tissues therefore seems unnecessary, 
wasteful and a potential cause of toxicity. The developments of over past decades 
indicate explicit progress in the area of controlled and targeted drug delivery. 
 Quantitative targeted drug delivery involves a number of essential bio ligands 
for physiologic cell need and bio signaling.  These operated through bioports referred 
to as receptors. The ligand-receptor interactions are highly stereo specific.  Thus 
ligands or receptors could be exploited for site/cell specific drug delivery in a well-
defined manner. Selective drug delivery or targeting seeks to improve upon the 
benefit/risk ratio associated with drugs. Approaches are being adopted either to 
control the distribution of drug by incorporating  in a carrier system by altering the 
structure of the drug at the molecular level, or by controlling the input of the drug into 
the bio environment to ensure a programmed and desirable bio distribution. 
The efforts to improve drug effectiveness in therapeutics have been assisted by 
parallel developments in molecular and cell biology. Such developments supported 
the successful generation of target oriented drug delivery systems. 
Target therapy remains an unachieved goal; however the idea stimulated a 
long series of experiments that propounded the philosophy of targeting of drugs and 
genes are attracted present generation of researchers towards the problems and 
prospects associated with the concept. 
A number of essential aspects should be considered for the designing of drug 
delivery systems to achieve this goal include target, carrier, ligand (s) and physically 
modulated components. 
Targeted drug delivery implies for selective and effective localization 
pharmacologically active moiety at pre identified targets in therapeutic concentration, 
while restricting its access to non-target normal cellular linings, thus minimizing toxic 
effects and maximizing therapeutic index.  
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1.1.  CARRIERS OF TARGETED DRUG DELIVERY SYSTEM1: 
Targeted drug delivery sometimes called smart drug delivery. It is a method of 
delivering medication to a patient in a manner that in increase the concentration of 
medication in some part of the body relative to others. The goal of targeted drug 
delivery system is to prolonged, localize, target and have precede drug interaction 
with the diseased tissue. Advanced to targeted release system is the reduction in the 
frequency of the dosage taken by the patient, having more uniform effect of the drug, 
reduction of side effect, and reduction fluctuation in circulation drug level. 
Targeted drug delivery system has been developed to optimize regenerative 
techniques. The system is based on method that delivers a certain amount of a 
therapeutic agent for a prolonged period of time to a target diseased area within the 
body. This helps maintain the required plasma and tissue drug levels in body. 
Therefore avoid any damage to the healthy tissue via drug. The drug delivery system 
is highly integrated and requires various disciplines, to optimize this system. Carrier 
is one of the most important entities essentially required for successful transportation 
of the loaded drug(s).  They are drug vectors, which sequester, transport and retain 
drug enroute, while elute or deliver it within or in the vicinity of target. Carrier can do 
so either through an inherent characteristics or acquired (through structural 
modification), to interact selectively with biological targets, or otherwise they are 
engineered to release the drug in the proximity of target cell lines for effective 
pharmacological actions. 
An ideal carrier engineered as targetable device should have following 
features: 
• Must be able to cross anatomical barrier 
• Must be recognized specifically and selectively by the target cells. 
• Linkage of the drug and directing unit (ligand) should be stable in plasma.  
• Should be non-toxic, non-immunogenic and biodegradable after recognition and 
release of drug moiety. 
Several carriers were used as pilot molecules to selectively deliver the drug to 
the intended cells have been reported. Based on the nature of their origin they are 
categorize 
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Table: 1. CARRIER SYSTEMS USED FOR TARGETED DRUG DELIVERY 
 
S. No Category Example 
1 Colloidal Carriers 
a) Vesicular systems 
Liposomes, Niosomes, Pharmacosomes, Virosomes, 
Immuno liposomes 
b) Micro particulate systems 
Microparticles, Nanoparticles, Magnetic 
Microspheres, Albumin Microspheres, Nanocapsules. 
2 Cellular Carriers Resealed erythrocytes, serum albumin, antibodies, 
platelets, leukocytes. 
3 
Supra molecular 
delivery systems 
Micelles, reverse micelles, mixed micelles, 
polymeric micelles, liquid crystals, lipoproteins, 
synthetic LDL. 
4 
Polymer based 
System 
Signal sensitive, Mucoadhesive, Biodegradable, 
Bioerodible. 
5 
Macro 
molecular 
carriers 
a) Proteins, glycoproteins, neo glycoproteins, 
artificial viral   envelopes. 
b) Glycosylated water soluble polymers (poly-
lysine). 
c) Mabs, Immunolgical Fab fragments, antibody 
enzyme complex. 
d) Toxins, immunotoxin & rCD4 toxin conjugates. 
e) Lectins & polysaccharides. 
 
1.2 LEVELS OF DRUG TARGETING: 
Dependability of a carrier system relies on exploiting both, intrinsic pathway 
these carriers follow and the bio protection that they can offer to drugs during transit 
through the body. The various approaches of vectoring the drug to the target site can 
be classified as: 
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Fig; 1 level of drug targeting 
 
• Passive targeting 
• Inverse targeting 
• Active targeting (ligand mediated and physical targeting) 
• Dual targeting 
• Double targeting 
• Combination targeting 
 
Passive targeting 
Systems that target the systemic circulation are generally characterized as 
“passive” delivery systems. In this system targeting occurs because of the body’s 
natural response to the physicochemical characteristics of drug carrier system. The 
ability of some colloids to be taken up by the RES especially in liver and spleen has 
made them as ideal vectors for passive hepatic targeting of drugs to these 
compartments. Passive capture of colloidal carriers by macrophages offers therapeutic 
opportunities for the delivery of anti-infective for disease conditions that involve 
macrophage cells of RES e.g. Leishmaniasis, brucellosis, and candidiasis. 
 
Inverse targeting 
Lazo and Hacker, 1986 developed inverse targeting. It is essentially based on 
successful attempts to avoid passive uptake of colloidal carriers by RES. This 
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effectively leads to the reversion of bio distribution trend of the carrier and hence the 
process is referred to as inverse targeting. One strategy to achieve inverse targeting is 
to suppress the function of RES by a pre-junction of colloidal carriers or 
macromolecules like dextrin sulphate. This leads to RES blockade and as a 
consequence impairment of host defence system. Alternative strategies include 
modification of the size, surface charge, composition, surface rigidity and 
hydrophilicity of carriers for desirable bio fate. 
 
Active targeting 
The facilitation of the binding of the drug-carrier to target cells through the 
use of ligands or engineered homing devices to increase receptor mediated 
localization of the drug and target specific delivery of drug (s) is referred to as active 
targeting. This can further be classified as 
 
1. First order targeting (organ compartmentalization) 
2. Second order targeting (cellular targeting) 
3. Third order targeting (intracellular targeting) 
 
1. First order targeting  
It refers to restricted distribution of the drug-carrier system to the capillary bed 
of a predetermined target site, organ or tissue compartmental targeting in lymphatic, 
peritoneal cavity, plural cavity, cerebral ventricles, lungs, joints, eyes, etc., represents 
first order targeting. 
 
2. Second order targeting 
The selective delivery of drugs to a specific cell type such as tumour cells and not to 
the normal cells is referred as second order drug targeting e.g. the selective drug 
delivery to the kupffer cells in the liver. 
 
3. Third order targeting 
The third order targeting is defined as drug delivery specifically to the intracellular 
site of target cells e.g. Receptor based ligand-mediated entry of a drug complex into a 
cell by endocytosis. 
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Ligand mediated targeting 
Ligand mediated active targeting could be achieved using specific uptake 
mechanisms such as receptor dependent uptake of natural low density lipoproteins 
(LDL) particles and synthetic lipid micro emulsions of partially reconstituted LDL 
particles coated with the apo proteins. The apo protein coat serves as a ligand for the 
LDL receptors expressed in the body. 
 
Physical targeting (Triggered release) 
The selective drug delivery programmed and monitored at the external level 
(ex vivo) with the help of physical means is referred to as physical targeting. 
 
Dual targeting  
The dual targeting employs carrier molecules, which have their own intrinsic 
antiviral effect thus synergies the antiviral effect of the loaded active drug. Drug 
conjugates can be prepared with fortified activity profile against the viral replication. 
 
Double targeting 
For a new future trend, drug targeting may be combined with another 
methodology, other than passive and active targeting for drug delivery systems. The 
combination is made between spatial control and temporal control of drug delivery. 
E.g. Mew and co-workers reported haematoporphyrin (HP)-anti-M-1antibody 
conjugates for the suppression of tumour following incandescent light exposure. 
 
Combination targeting 
Petit and Gombtz, 1998 have suggested the term combination targeting for the 
site-specific delivery of proteins and peptides. These targeting systems are equipped 
with carriers, polymers, and homing devices of molecular specificity that could 
provide a direct approach to target site.  
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1.3 PARTICULATE/COLLOIDAL DRUG CARRIER SYSTEM2 
The colloidal carriers based on biodegradable and biocompatible polymeric 
systems have largely influenced the controlled and targeted drug delivery concepts. 
Nanoparticles are sub-nanosized colloidal structures composed of synthetic or semi 
synthetic polymers. Nanotechnology represents an important technological revolution 
in 21st century. Nanotechnology is the study of nanoparticles, nanosuspension, 
nanoemulsion etc. Nanoparticle is a collective name for nanospheres and nanocapsule. 
Nanospheres have a matrix type structure. Drugs may be adsorbed at their surface, 
entrapped in the particle or dissolved in it. 
   
Fig: 2. Structures of Nanosphere and Nanocapsule 
 
 
 
 
Nanocapsule has a polymeric shell and an inner liquid core.  The active 
substance is usually dissolved in the inner core, but may also be adsorbed at their 
surface. 
Nanosuspension consist of essentially pure drug  and minimal quantities of 
surface stabilizing agents that may enable high dosing  with reduce toxicity provided 
toxic drug levels are not reached in vivo. It also provides sustained release at a level 
below the maximum tolerated dose yet at its therapeutically effective concentration. 
They are mainly used for parental drug delivery. A coarse solid suspension (10-100 
µm) has been produced for intramuscular and subcutaneous delivery of poor water 
soluble drug. 
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Table: 2 various carrier based dosage forms3 
s.no 
Carrier system Size range Features 
Method of 
prepration 
 
1 
 
Nanoparticles 
 
10-1000 nm 
Submicron-sized 
Colloidal systems, 
biodegradable (or) not 
Emulsion 
solvent 
evaporation 
method 
 
2 
 
Polymeric     
nanoparticles 
 
10-1000 nm 
Sub-nanosized colloidal 
structure  composed of 
synthetic 
or semi- synthetic 
polymers 
Nano 
precipitation 
method 
3 Liposomes 25-100 nm 
Microscopic vesicles 
composed of one or more 
concentric lipid bilayer, 
separated by water or 
aqueous buffer 
compartments 
Nano 
precipitation 
method 
 
4 
Solidlipid 
nanoparticle 50-1000 nm 
Submicron colloidal 
carriers containing solid 
hydrophobic core having a 
monolayer of 
phospholipids coating. 
High-pressure 
homogenization 
Micro emulsion 
formation 
precipitation as 
lipid  
nanopellets 
 
5 
 
Lipid emulsion 
 
Lipid 
globule 
1-100 nm 
Multi component fluid 
made of water. A 
hydrophobic liquid, or 
several surfactants 
resulting in a stable system 
o/w 
w/o 
w/o/w 
 
 
6 
 
Lipidmicrotubles 
/microcylinders 
 
1um 
Self-organizing system in 
which surfactants 
crystallize into tightly 
packed bilayers that 
spontaneously form 
cylinders 
 
Self-
emulsification 
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7 
 
Nanotubes and 
nanowires 
 
Self-assembling sheet of 
atoms arranged in the form 
of tubes and thread-like 
structures of nanoscale 
range 
 
Chemical 
evaporation 
dispersion 
 
8 
 
Functionalized 
nanocarriers/ 
quantam dots 
 
Combination of 
functionalities of 
biomolecules and non-
biologically derived 
molecular species 
 
9 
 
Ceramic 
nanoparticles 
 
50 nm 
Made up of inorganic 
(ceramic) compounds such 
as silica, titania and 
alumina 
Emulsion 
solvent 
evaporation 
method 
 
10 
 
Ethosomes 
 
Noninvasive delivery 
carriers that enable drugs 
to reach the deep skin and  
systemic circulation 
Ethanol 
injection-
sonication 
method 
 
11 
 
Lipospheres 
 
0.2-100 um 
Water dispersible solid 
micro particles composed 
of solid hydrophobic fat 
core stabilized by a mono 
layers of phospholipids 
molecules embedded in  a 
micro particles surface 
Melt method, 
Co-solvent 
method, 
Pre 
incorporation 
into lipophilic 
carrier 
 
12 
 
Multi composite  
ultrathin 
capsules 
 
50 nm  few 
micron 
Molecular assemblies of 
tailored architecture 
having layer-by-layer 
adsorption of oppositely 
charged macromolecules 
on to colloidal particles 
Langmuir-
Blodgett 
technique and 
chemisorption 
from solution 
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13 Pharmacosomes  
Pure drug vesicles formed 
by the amphiphilic drugs 
 
 
14 
 
Niosomes 
 
12-16 
micron 
Non-ionic surfactant 
vesicles are bi-layered 
structures 
Ether injection 
method. 
 
15 
 
Dendrimers 
 
Macromolecular 
compounds that consist of 
a series of branches around 
an inner core 
 
Polymerization 
16 Collidosomes 
 
Solid microcapsules which 
are hollow, elastic shells 
Self-assembly 
of colloidal 
particles at the 
interface of 
emulsion 
droplets 
 
17 
 
Discomes 
 
12-16 
microns 
Non-ionic surface active 
agents based discoidal 
vesicles. 
Ether injection 
method 
18 Aquasomes 60-300 nm 
The particles core is 
composed of non-
crystalline calcium 
Self-assembling 
by co-
precipitation 
method 
  
Market Potential4 
Nanotechnology has become the focus of immense expectation in terms of 
market potential and efficiency. Over 200 companies are engaged in manufacturing 
nanomedicine. The market amounts to $ 6.8 billion in the year 2005 about 75% of this 
income were from drug delivery products.  It is expected to reach $ 12 billion by the 
end of 2012 due to the launch of more nanoproducts which is under research. 
Nanobased diagnostic products are about $ 12 million. 
 
The number of products based on polymeric microparticles on the markets is 
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limited.  After the introduction of the first wave of products, there was only a limited 
increase in the number of micro particulate products. Hence polymeric nanoparticle 
was introduced.   
 
Nanoparticles,5are referred as nanosized colloidal particle, ranging in size 
from  10-1000 nm in which  drug is dissolved, dispersed, attached, adsorbed or 
encapsulated by polymers which may be synthetic, semi-synthetic or biodegradable. 
Nanoparticles are ultra-fine colloidal structures, which carry drug particles that may 
not dissolve but remains suspended in medium.  Due to their small size nanoparticles 
can be easily absorbed into RES and other systems of body and give a quick & better 
action. 
 
1.4 POLYMERIC NANOPARTICLES5 
These are colloidal particles ranging in the size from 10-1000 nm.  They 
consist of macromolecular materials and can be used therapeutically, e.g. as adjuvant 
in vaccines, drug carriers, in which the active principle (Drug or biological active 
material) is dissolved, entrapped or encapsulated and the active principle is adsorbed 
or attached. 
The concept of using nanoparticle for drug delivery was developed first by 
Speiser and co-workers in the late 1960 and early 1970s when cross-linked poly 
acrylamide nanoparticles are produced by the polymerization of acrylamide and NN –
Methylene bisacrylamide after secondary solubilization in an organic solvent such as 
hexane. The active ingredients, drug or antigen, were incorporated into the solubilized 
aqueous phase. Because of the larger amount of organic solvents and surfactants used 
for the manufactures to develop nanoparticle, the process is now only of historical 
interest. Polymeric nanoparticles are composed of biodegradable or bio stable 
polymers and copolymers. The active agents can be; 
(i) Entrapped or encapsulate within the particles 
(ii) Physically adsorbed on surface,(or) 
(iii) Chemically linked to the surface of the nanoparticles. 
Nanoparticles have been explored for the delivery of anti-HIV molecules and it 
used to Targeted antiretrovirals; 
(i) Macrophages/ monocytes 
(ii) CNS which act as viral reservoir sites during HIV. 
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Polymeric nanocarrier-based antiretroviral therapy: 
Polymeric nanocarriers are generally composed of polymers like gelatin, 
chitosan, poly (D, L-lactide-coglycolide), poly (a-caprolactone) etc. These are again 
classified into 3 types: polymeric micelles, nanoparticles & dendrimer type. Among 
polymeric nanocarriers, dendrimers and nanoparticles are important classes. Most of 
the nanoparticle based targeted delivery of antiretroviral drugs has been studied to 
target cells of the mononuclear phagocytic system (MPS), such as the 
monocytes/macrophages (Mo/Mac) that act as a reservoir for the HIV virus. 
 
Advantages of polymeric nanoparticles 
• Reduction of toxicity and occurrence of adverse reactions 
• Better drug utilization 
• Controlled rate of drug release 
• Specific site of drug release 
• Greater patient convenience and better patient compliance 
• Enhancement of the therapeutic effectiveness of the drug i.e. the overall 
• pharmacological response per unit dose 
• Method of preparations are reproducible 
• Easy handling of nanoparticles prepared in the powder form 
• Nontoxic and biodegradable 
• Relatively cheaper and stable 
• No swallowing problems in case of oral administration. 
Polymers used in Preparation of Polymeric Nanoparticles 
 Polymers used in manufacturing of polymeric nanoparticles are of two types 
1. Natural hydrophilic polymers (Proteins and polysaccharides) 
2. Synthetic hydrophobic polymers (Poly lactic acid and PLGA) 
 
Natural Hydrophilic polymers: 
Albumin, Gelatin, legumin or vicilin as well as polysaccharides like alginates 
or agarose have been extensively studied and characterized. These macromolecules 
are used due to their intrinsic biodegradability and biocompatibility. 
Disadvantage with natural polymers are: 
 Batch to batch variation 
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 Conditional biodegradability. 
 Antigenicity. 
Synthetic Hydrophobic polymers: 
Polymers which are used for microspheres preparation are used for 
nanoparticle preparation. Most of them are hydrophobic in nature. The polymers are 
either pre-polymerized or synthesized during nanoparticles preparation. 
 
Table: 3. Synthetic polymers used for preparation of nanoparticles. 
 
S.No Classification Examples 
1 
Pre-
polymerized 
Poly (ε-caprolactone) (PECL) 
Poly (lactic acid) (PLA) 
Poly (lactide-co-glycolide)(PLGA) 
Poly styrene 
2 
Polymerized 
insitu 
Poly (isobutylcyanoacrylates)(PICA) 
Poly (butylcyanoacrylates)(PBCA) 
Poly hexylcyanoacrylate (PHCA) 
Poly methyl (methacrylate)(PMMA) 
Co polymer of aminoalkymethacrylate 
methyl methacrylate 
 
Fig 3: Mechanism of formation of polymeric nanoparticles in drug delivery 
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1.5 PREPARATION TECHNIQUES OF NANOPARTICLES6,17: 
The selection of the appropriate method for the preparation of nanoparticles 
depends on the physicochemical characteristics of the polymer and the drug to be 
loaded. 
Two types of systems with different inner structures are apparently possible 
they are: 
1. A matrix type system consisting of an entanglement of oligomer or polymer units 
(nanoparticles/nanospheres) 
2. A reservoir type of system comprised of an oily core surrounded by an embryonic 
polymeric shell (nanocapsules) 
 
The drug can either be entrapped within the reservoir or the matrix or be 
adsorbed on the surface of these particulate systems.  The polymers are strictly 
structured to a nanometric size range using appropriate methodologies. They are 
classified as: 
Amphiphilic macromolecule cross-linking 
 Heat cross-linking 
 Chemical cross-linking 
Polymerization based methods 
 Polymerization of monomers insitu 
 Emulsion (micellar) polymerization 
 Dispersion polymerization 
 Interfacial condensation polymerization 
 Interfacial complexation 
Polymer precipitation methods 
 Solvent extraction/evaporation 
 Solvent displacement (nanoprecipitation) 
 Salting out.  
 
PREPARATION OF NANOPARTICLE USING POLYMER PRECIPITATION 
METHOD: 
 The hydrophobic polymer and hydrophobic drug is dissolved in a particular 
organic solvent followed by its dispersion in a continuous aqueous phase, in which the 
polymer is insoluble. Precipitation of the polymer produces nanoparticles with drug 
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loaded in it. The external phase also contains the stabilizer. Depending upon solvent 
miscibility techniques they are designated as solvent/evaporation method. 
 
 Polymer precipitation can be brought out by increasing the solubility of the 
organic solvent in the external medium by adding an alcohol  
• By incorporating additional amount of water into the ultra-emulsion 
• By evaporation of organic solvent at room temperature or at accelerated 
temperatures or by using vacuum. Using an organic solvent is completely soluble 
in the continuous aqueous phase – nanoprecipitation. 
 
A. Solvent extraction method: 
  The preparation of nanoparticles starts with formation of conventional O/W 
emulsion between a partially water miscible solvent containing the polymer and the 
drug, and an aqueous phase containing the stabilizer. The subsequent removal of 
solvent (solvent evaporation method) or additions of water to the system so as to 
diffuse the solvent to the external phase (emulsification diffusion method) are the two 
variance of the solvent extraction method. 
 The classic procedure to prepare nanospheres is the polymer is solubilized in a 
solvent and dispensed in a gelatin solution by sonication to yield emulsion (O/W), 
then the solvent is eliminated by evaporation. For the evaporation purpose, apart from 
sonication, high speed/pressure homogenization methods are widely employed. The 
homogenizer breaks the initial coarse emulsion in nanodroplets (nano fluidization), 
yielding nanospheres with a narrow-size distribution.  
 
B. Double Emulsion solvent Evaporation method: 
 Emulsion solvent evaporation technique has been further modified and a 
double emulsion (or multiple emulsion) of water in oil in water type has been used. 
Following evaporation of the organic solvent(s) nanoparticles are formed which are 
then recovered by ultracentrifugation, washed repeatedly with buffer and lyophilized. 
 
 Polymer are dissolved separately in aqueous and organic phases respectively 
containing stabilizer and subjected to ultra-sonication to yield water in oil emulsion 
(W/O). This W/O is further added to a PVA aqueous solution to yield the water in oil 
in water double emulsion (W/O/W). The organic solvent is allowed to evaporate 
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while being stirred first at atmosphere pressure for 16 h and then gradually at reduced 
pressure to yield nanoparticles. 
 
C. Solvent Displacement or Nanoprecipitation 
 This method based on interfacial deposition of a polymer following 
displacement of a semi-polar solvent miscible with water from a lipophilic solution. 
Solvent displacement method involves the use of an organic phase, which is 
completely soluble in the external aqueous phase. The organic solvent diffuses 
instantaneously to the external aqueous phase, inducing immediate miscibility of both 
the phases. Consequently, neither separation nor extraction of the solvent is required 
for the polymer precipitation. After nanoparticles preparation, the solvent is 
eliminated and the free flowing nanoparticles can be obtained under reduced pressure. 
This method is particularly useful for drugs that are slightly soluble in water. 
 If the drug is highly hydrophilic, it diffuses out into the external aqueous 
phase, where as if the drug is highly hydrophobic, it may precipitate in the aqueous as 
nanocrystals, which further grown during storage. In the case of hydrophilic polymer, 
an aqueous solution of polymer is dispersed or emulsified in oil phase. The 
precipitation of polymer proceeds on addition of acetone. 
 
D. Salting out: 
  The method involves incorporation of a saturated aqueous solution of 
polyvinyl alcohol (PVA) into an acetone solution of the polymer under magnetic 
stirring to form an O/W emulsion. However, the process differs from 
nanoprecipitation technique as in the latter the polymeric solution is completely 
miscible with the external aqueous medium. But in salting out technique, the 
miscibility of both the phases is prevented by the saturation of the external aqueous 
phase with PVA. The precipitation of the polymer occurs when a sufficient amount of 
water is added to external phase to allow complete diffusion of the acetone from 
internal phase into the aqueous phase. 
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Table 4: Methods, Polymer and drug that are used for Nanoparticles 
preparation7: 
S.No Methods and polymer employed Incorporated or absorbed drug 
1 
Emulsion polymerisation in 
continous aqueous phase 
 
 Polymethyl  methacrylate 5-flurouracil, Indomethacin 
 
Polymethylmethacrylateco-
polymers 
Doxorubicin 
 Polymethyl cyanoacrylate 
Actinomycin D, vinblastine, 
Methotrexate, 
 Polybutyl cyanoacrylate Progesterone, Pilocarpine. 
2 
Emulsion polymerization in a 
continous organic phase 
 
 Polyacrylamide Norephedrine 
 Polymethyl cyanoacrylate Triamcinolon, fluorescein 
3 Interfacial polymerization  
 Polyisobutyl cyanoacrylate Indomethacin, Insulin 
4 Interfacial  deposition  
 Poly D, L –lactide Indomethacin 
5 
Denaturation of natural 
macromolecules in oil emulsion 
 
 Serum albumin Doxorubicin, Primaquine 
6 Carbohydrate nanoparticles  
 Polyacrylstarch Trimethoprim, primaquine 
7 
Nanoparticle formation by 
desolvations of macromolecules 
 
 Gelatin Mitomycin C,  Metronidazole 
 Albumin Insulin 
8 Solvent evaporation  
 Eudragit RL Indomethacin 
 Polylactic acid Triamcinolone. 
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1.6 PURIFICATION OF NANOPARTICLE: 
 Since most of the nanoparticles are indented for parental administration, 
purification of the raw nanoparticulate suspensions is essential. Depending on the 
method of preparation, the following potentially toxic and undesirable preparation 
additives can be present in the raw suspensions: organic solvents, surfactants, 
stabilizers, electrolytes and large polymer aggregates.   
Purification is needed to separate free drug from the drug bound to the 
particles in order to avoid a burst effect at the time of injection. Polymer aggregates 
can be removed by filtration through sintered glass filters. Organic solvents especially 
chlorinated solvents must be absolutely eliminated below the pharmacopoeia limits. 
Poloxamer 188 and polysorbate 20, 40, and 80 are the surfactants approved for usage 
in injection form. 
 
The purification technique involves the following: 
1) Ultra-centrification. 
2) Gel filtration. 
3) Cross-flow filtration. 
4) Dialysis 
 
Gel filtration; 
High molecular weight substance and impurities are difficult to remove. 
 
Fig 4; Gel filtration chromatography 
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Cross flow filtration; 
 
 
Fig 5; cross flow filtration 
 
1.7 FREEZE – DRYING8: 
On keeping the nanoparticles in aqueous medium during storage, 
biodegradation of polymer, drug leakage, and drug degradation may occur. To 
improve the physicochemical stability of the nanoparticles drying step is required. 
Heat drying may be harmful for thermoliable active compounds. Moreover due to the 
low glass transition temperature of poly (α- hydroxycarboxylic acid) the particles 
induces fusion or aggregation when heated at elevated temperatures. Therefore freeze-
drying represents most applicable alternative method. 
 
 
Fig 6; Freeze dried nanoparticles 
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The nanoparticulate suspensions are frozen at temperature ranging from -40o C 
to -60oC or in liquid nitrogen. Depending upon the amount of water to be evaporated, 
they are freeze-dried for periods ranging from 24 to 90 h, at a pressure below 10 Pa. 
Ease of re-dispersion of freeze-dried particles depends on the particle coating. 
Usually particles are prepared in the presence of poloxamer, polysorbate, PVAL, or 
sodium dodecyl sufate and they are readily re-dispersible in water. Residues of these 
stabilizers or surfactants display cryoprotective characteristics and therefore facilitate 
aqueous reconstitution. 
If the freeze- dried particles are not easily re-dispersible then addition of 
cryoprotective agent may be necessary. Dextrose, lactose, trehalose, sucrose and 
mannitol are the most widely used. Addition of cryoprotectant increases the tonicity 
of the final re-dispersed formulation. 
 
1.8 STERILIZATION30 
Nanoparticles are to be used as injections and should be sterile and 
apyrogenic. Aseptic processing in a clean room environment is costly, difficult to 
achieve and inherently risky with respect to microbial contamination of the finished 
product.  
 The nanoparticle sterilization carried by membrane filtration. The membrane 
filter pore size 0.22 um in some case micro-organisms and nanoparticles may be 
larger in size (0.25-1.0um). So this sterilization process is not more effective. 
            In this case the nanoparticles sterilization carried by aseptic condition with 
terminal sterilization process. The terminal sterilization is carried out by autoclaving. 
The processing under aseptic condition is not completely safe a terminal sterilization 
step is required to ensure the microbiological safety of final product. 
Radiolytic degradation of the active compound can occur in certain cases with 
the formation of toxic or inactive by-products. Independent of the degradation 
mechanism, reduction in polymer molecular weight may significantly influence drug 
release patterns. Degradation of the polymer not only affects drug release, also affect 
the in vivo resorption of the drug carrier. 
Sterile nanoparticles must meet pharmacopeia requirements relating to sterility 
and apyrogenicity. The nanosuspensions should be tested for sterility by membrane 
filtration of the test specimens followed by incubation of the membrane in a culture 
                                  
INTRODUCTION 
 
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai. 21 
 
medium of choice. Pyrogens are tested by measuring the rise of temperature of rabbits 
following intravenous administration of the product, and bacterial endotoxins are 
assayed by Limulus Amebocyte Lysate (LAL). 
 
1.9 EVALUATION OF NANOPARTICLES 
 The prepared nanoparticles are evaluated for various parameters they are: 
1. Yield 
2. Drug loading 
3. Entrapment efficiency 
4. Size and morphology 
5. In vitro drug release studies 
6. Stability testing 
 
Yield: 
 Percentage yield is of great importance if one considers industrial applications 
with costly raw materials. It plays crucial role in determining whether the preparation 
procedure chosen for incorporating a compound into the polymeric particles is 
efficient. The overall yield of a procedure is simply expressed as, 
 
 
   Initial amount of raw materials 
Yield (%) =               X 100 
           Amount of nanoparticles 
 
The initial amount of raw materials corresponds to the amount of active 
compound plus polymer however because of a certain amount of stabilizing agents or 
surfactants being adsorbed during the preparation, a correction factor should be 
introduced. 
 
Initial amount of raw materials 
Yield (%) =                 X 100 
            Amount of nanoparticles X (1-Fraction of residual stabilizing agents) 
                          
 
Drug loading:
                        The drug loading or pay load or drug content is expressed as, 
     Amount of drug in nanoparticles 
Drug loading =                X 100 
       Amount of nanoparticles 
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Entrapment efficiency (E.E): 
 Drug entrapment efficiency represents the proportion of the initial amount of 
drug, which has been incorporated into or absorbed onto the particles. It is defined as, 
 
% drug loading 
E.E (%) =               X 100 
% of initial content X (1-Fraction of residual stabilizing agents) 
 
Due to the small size of the nanoparticles, the determination of drug loading is 
done after separation of free drug from bound drug. Drug loading can be assessed 
after ultracentrifugation of a nanoparticulate suspension by dissolution of the 
sediment in an appropriate solvent and subsequent analysis. Additional analysis of the 
free drug in the supernatant may be used to confirm the results. Depending upon the 
analytic, methods such as spectrophotometry, spectrofluorophotometry, high 
performance liquid chromatography or liquid scintillation counting can be used to 
determine the drug loading. 
 If the particles are purified by cross-flow filtration and subsequently freeze-
dried, the particles can be directly dissolved in an adequate solvent. 
 
Size and Morphology: 
 Photon Correlation Spectroscopy (PCS), Transmission Electron Microscopy 
(TEM) and Scanning Electron Microscopy (SEM) are most commonly used tools for 
studying the particle size of nanoparticles. 
Photon Correlation Spectroscopy (PCS) is a laser light scattering method 
suitable for measurement of particles ranging from 5 nm to 5 µm.  The PCS device 
consists of a laser, a temperature controlled cell, and a photomultiplier. The light 
scattered from a colloidal dispersion is detected on photomultiplier and transferred to 
a correlate for the calculation of a correlation function. This function is then processed 
to calculate the mean size of the particles. The advantage of this technique is the case 
of sample preparation. To be analyzed, the particles need to be diluted in a solvent, 
which is generally double filtered water. 
Scanning Electron Microscopy is widely used for the field of nanocarriers. It 
has high resolution and relatively easy sample preparation. However, to be analyzed 
the sample should withstand a high vacuum. To visualize the particles, they have to be 
conductive and therefore, coating of the surface of the sample with gold is required. 
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The coating thickness is at least 20 nm. Removal of stabilizing agents added during 
the preparation of the particles is essential. Otherwise, depending on the amount of 
these additives, the particles are partially or completely hidden in a matrix of 
additives. 
Photon Scanning Tunneling microscope also called as Atom force microscopy 
enable visualization of nanoparticles at atmospheric pressure without gold coating but 
the resolution is still less than SEM. 
 
INVITRO RELEASE STUDIES41 
 In vitro release studies should be in principle is useful for quality control as 
well as for the prediction of in vivo kinetics. Unfortunately, due to the very small size 
of the particles, the release rate observed in vivo can differ greatly from the release 
obtained in a buffer solution. Depending on the type, drug release from nanoparticles 
can take place through following two processes: 
 The drug may diffuse out of the carrier through solid matrix: to allow complete 
release from the carriers 
 The solvent may penetrate the nanoparticles and dissolve the drug, which then 
diffuses out into the release medium. 
 The carrier may be degraded by its surroundings as long as this process is faster 
than diffusion the release process is said to be erosion controlled. 
 
In vitro release kinetics of a drug entrapped in nanoparticles can be evaluated 
by several experimental methods. 
1. Dialysis 
2. In situ method 
3. Sample and separation techniques 
4. Ultra filtration at low pressure. 
5.  
Dialysis: 
 Nanoparticles suspended in a small volume of release medium, are separated 
from a large bulk of sink medium by a dialysis membrane, which is permeable to the 
drug. The active substance is released from the nanoparticles and diffuses through the 
membrane. The released drug is assayed in the receptor phase.  
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1.10 APPLICATIONS OF NANOPARTICLES: 
 Nano medicines: nanodrug, medical devices, tissue engineering etc. 
 Ceramic based nanoparticles for entrapping therapeutic agent for 
photodynamic therapy, in this method the photosensitive drug/dye is entrapped 
with ceramic carrier. These ceramic nanoparticles are widely used for skin and 
therapeutic purpose. 
 The thermo sensitive nanoparticles may be used for selective release of the 
content after specific localization like photodynamic therapy 
  Materials: nanoparticles, carbon nanotubes, biopolymer, paints, coating. 
 
Table; 5.Various applications of Nanoparticles/Nanocapsules 
 
S.NO Application Materials Purpose 
1 
 
Intracellular 
targeting 
Poly(alkylcyanocrylate)poly
ester, nanoparticles with 
anti-neoplastic or antiviral 
agent 
Target reticulo-endothelial 
system for intracellular 
infection 
2 
 
Vaccine 
adjuvants 
Poly(methylmethacrylate) 
nanoparticles with vaccines 
oral and intramuscular 
immunization 
Enhances immune response, 
alternate acceptable 
adjuvant 
3 
 
DNA 
delivery 
DNA-gelatin nanoparticles, 
DNA-chitosan 
nanoparticles, PDNA-
Poly(DL-lactide-co- 
glycolide) nanoparticle 
Enhanced delivery and 
significantly higher 
expression levels 
4 
 
Cancer 
therapy 
Poly (alkylcyanoacrylate) 
nanoparticles with 
Anticancer agents, 
oligonucleotides 
Targeting reduced toxicity, 
enhanced uptake of 
antitumor agents, improved 
in vitro and in vivo stability 
5 
Per oral 
absorption 
Poly (methacrylates) 
nanoparticles with proteins 
and therapeutic agents 
Enhanced bioavailability 
protection from G.I.T 
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1.11 INTRODUCTION ABOUT HIV; 
Human Immunodeficiency Virus type 1 (HIV-1) infection is the major cause 
of impaired immune system function that leads to progression of disease and death in 
patients with Acquired Immunodeficiency Syndrome (AIDS). Antiretroviral therapy 
has been limited by several factors, such as its inherent toxicity, insufficient efficacy, 
and drug resistance. In 2007, it was estimated that the total number of people infected 
by HIV accounted for around 33 million, while another 25 million more have already 
died since the first reported cases in 1980. In 1980s first antiretroviral drugs were 
introduced and after the development of resistance when treated with single drug 
regimens, Highly Active Antiretroviral Therapy (HAART) was introduced in the 
late1990s, comprising the intense use of combination drug regimens. Several classes 
of ARVs including i) nucleoside reverse transcriptase inhibitors (NRTIs) ii) non-
nucleoside reverse transcriptase inhibitors (NNRTIs) iii) protease inhibitors (PIs)  iv) 
intergraded inhibitors,  v) entry inhibitors. The primary rationale for using multiple 
agents is to disrupt HIV replication at multiple points in the lifecycle. Each of these 
combination regimens often comprises two nucleoside analogues and a PI to achieve 
synergistic effect. These therapeutic combinations are referred as the highly active 
ARV therapy (HAART) in general, less effective for the treatment of CNS 
complications than other AIDS-related illnesses. By using targeted nanoparticle drug 
delivery systems, anti-HIV drugs can accumulate in HIV-infected tissues or cells 
selectively and quantitatively, while their concentration in non-infected tissues or 
cells should be much lower. Therefore, side effects are reduced, lower doses are 
needed and drug administration regimens are simplified. Alongside, inadequate 
physical, chemical properties of most of these antiretroviral drugs (e.g. poor 
solubility, permeability, and stability) impair optimal absorption, bio-distribution, and 
sustained antiretroviral effect, thus contributing to poor clinical outcome. In order to 
solve these problems, several new and improved delivery systems and dosage form 
have been proposed in the literature.  
 
Nanotechnology-based systems for HIV/AIDS treatment; 
The basic concept behind the use of nanotechnology-based systems for 
antiretroviral drug delivery is related with the modulation of pharmacokinetics of 
incorporated molecules with this association, the properties that govern drug 
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absorption, distribution, and elimination while in the human body are determined not 
by the drug properties, rather by the nanosystems physical–chemical properties, 
particularly surface exposed molecules and electric charge, and its size. General 
properties of nanosystems that favor their use in antiretroviral drug delivery are well 
known and include versatility (virtually all drugs may be encapsulated), good toxicity 
profile (depending on used excipients), possibility of drug-release modulation, high 
drug payloads, relative low cost, easiness to produce and possible scale-up to mass 
production scale . Their ability to incorporate, protect and promote the absorption of 
non-orally administrable anti-HIV drugs, namely mono or oligonucleotides, is of 
importance to improve the bioavailability of several molecules. Once bioavailable, 
protection of incorporated drugs from metabolism is a favorable feature of 
nanosystems, allowing prolonged drug residence in the human body, thus reducing 
needed doses and prolonging time between administrations. The use of 
nanoparticulate systems for antiretroviral drug delivery may be particularly 
advantageous for targeted delivery, namely to cells or organs that are directly 
implicated in HIV/AIDS. This can be achieved either by passive or active targeting.  
Passive targeting is based in the inherent properties of different nanosystems, 
namely size, particle shape, and surface charge, which can modulate its 
bioavailability, biodistribution and targeting, in the case of active targeting, 
nanotechnology-based systems are conveniently modified, most commonly by surface 
attachment of specific ligands that are able to recognize target cells or sites, and 
escape bio elimination processes. One important limitation of many current 
antiretroviral drugs is their unavailability to circumvent efflux pumps (particularly P-
glycoprotein) that are present, for instance, in the membrane of several HIV-target 
cells and BBB endothelium. Nanoparticulate systems ability to escape these bio 
elimination processes is an added advantage in order to avoid this particular resistance 
mechanism to drug delivery, namely to the CNS. Thus, increasing the amount of 
available antiretroviral drugs and its residence time at target sites allow thinking about 
dose reduction and, consequently, simpler but improved regimens with less adverse 
effects and increased compliance. Also, the possibility of incorporating different 
antiretroviral drugs in the same delivery system and modulate their release 
individually has been shown possible. This fact may contribute to simplify drug 
administration schedules, being an important objective towards the reduction of 
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antiretroviral drug administration errors. Nanosystems seem to be able to reduce 
antiretroviral drugs toxicity, namely at the cellular level, providing that rigorous 
selection of materials and adequate preparation techniques are assured. Even if drug 
uptake is increased when encapsulated in nanocarriers, cell toxicity seems to be 
diminished, probably due to the slow-release properties of these systems. This 
possibility is particularly interesting taking in consideration the well-known toxicity 
associated with anti-HIV therapy. However, the effects of the possible 
bioaccumulation of nanosystems components have not been fully addressed and may 
point of concern for prolonged used. Lastly, nanosystems may allow obtaining 
antiretroviral medicines with adequate shelf-life, even if this issue has not yet been 
fully explored. Formulation should be carefully performed and long-term stability 
studied since antiretroviral drug-loaded nanotechnology-based systems may undergo 
several physical–chemical changes that can potentially impair efficacy and safety. 
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2. REVIEW OF LITERATURE 
 
S. Tamizhrasi18 et al., (2009) prepared and evaluated polymethacrylic acid 
nanoparticles containing lamivudine in different drug to polymer ratio by 
nanoprecipitation method. SEM indicated that nanoparticles have a discrete spherical 
structure without aggregation. The particle size of the nanoparticles was gradually 
increased with increase in the proportion of polymethacrylic acid polymer. The drug 
content of the nanoparticles was increasing on increasing polymer concentration up to 
a particular concentration. No appreciable difference was observed in the extent of 
degradation of product during 60 days in which, nanoparticles were stored at various 
temperatures. FT-IR studies indicated that there was no chemical interaction between 
drug and polymer and stability of drug. The in vitro release behavior from all the drug 
loaded batches was found to be zero order and provided sustained release over a 
period of 24 h. The developed formulation overcome and alleviates the drawbacks 
and limitations of lamivudine sustained release formulations and could possibility be 
advantageous in terms of increased bioavailability of lamivudine. 
 
Ashish Deva19 et al., (2010) developed Poly (lactic acid) (PLA)/chitosan (CS) 
nanoparticles by nanoprecipitation method for anti-HIV drug delivery applications. 
The prepared PLA/CS nanoparticles were characterized using DLS, SEM, and FTIR. 
The hydrophilic antiretroviral drug Lamivudine was loaded into PLA/CS 
nanoparticles. The encapsulation efficiency and in vitro drug release behavior of drug 
loaded PLA/CS nanoparticles were studied using UV spectrophotometer. In addition, 
the cytotoxicity of the PLA/CS nanoparticles using MTT assay was also studied. The 
in vitro drug release studies showed that drug release rate was lower in the acidic pH 
when compared to alkaline pH. This may due to repulsion between H+ ions and 
cationic groups present in the polymeric nanoparticles. Drug release rate was found to 
be higher in the 6% drug loaded formulation when compared to 3% drug loaded 
formulation. These results indicated that the PLA/CS nanoparticles are a promising 
carrier system for controlled delivery of anti-HIV drugs. 
 
Pravin Patil20 et al., (2009) prepared solid lipid nanoparticles by emulsion solvent 
diffusion technique. The formulations were characterized for surface morphology, 
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size and size distribution, percent drug entrapment and drug release. The optimum 
rotation speed, resulting into better drug entrapment and percent yield, was in the 
range of 1000-1250 r/min. In vitro cumulative % drug release from optimized SLN 
formulation was found 40-50 % in PBS (pH-7.4) and SGF (pH-1.2) respectively for 
10 h. After 24 h more than 65 % of the drug was released from all formulations in 
both mediums meeting the requirement for drug delivery for prolong period of time. 
 
Rubiana M.Marnardes21 et al., (2005) designed nanoparticles for Praziquantel using 
Poly (D, L-lactide-co-glycolide) (PLGA) as a carrier. The effects of some process 
variables on the size distribution of nanoparticles prepared by emulsion solvent 
evaporation method. The results showed that sonication time, PLGA and drug 
amounts, PVA concentration, ratio between aqueous and organic phases and the 
method of solvent evaporation have a significant influence on size distribution of the 
nanoparticles. 
 
Kathleen Dillen22 et al., (2006) prepared nanoparticles by water-in-oil-in-water 
(w/o/w) emulsification and solvent evaporation, followed by high-pressure 
homogenization techniques. Two non-biodegradable positively charged polymers, 
Eudragit RS100 and RL100, and biodegradable polymer poly (lactic-co-glycolic acid) 
or PLGA were used alone or in combination, with varying ratios. The formulations 
were evaluated in terms of particle size and zeta potential. Differential scanning 
calorimetric measurements were carried out on the nanoparticles and on the pure 
polymers Eudragit and PLGA. Drug loading and release properties of the 
nanoparticles were examined. The antimicrobial activity against Pseudomonas 
aeruginos and Staphylococcus aureus was determined. During solvent evaporation, 
the size and zeta potential of the nanoparticles did not change significantly. The mean 
diameter was dependent on the presence of Eudragit and on the viscosity of the 
organic phase. The zeta potential of all Eudragit containing nanoparticles was positive 
in ultrapure water (around + 21mV). No burst effect but a prolonged drug release was 
observed from all formulations. The particles activity against P.aeruginosa and 
S.Aureus was comparable with an equally concentrated ciprofloxacin solution. 
 
M.C. Venier-Julienne23 et al., (1996) prepared biodegradable poly (D, L-lactic acid-
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co-glycolic acid) copolymer (PLAGA) nanoparticles by the solvent evaporation 
process and to incorporate an antifungal antibiotic, amphotericin B. Blank 
nanoparticles obtained were 130 of 27 nm in diameter. When amphotericin B was 
added in the organic phase, the final suspension showed two populations due to 
unbound drug. Free amphotericin B was removed by contacting the nanoparticle 
suspension with an adsorbent polymer and subsequently ultra-filtering the medium. 
The drug payload was between 0.7 and 1.3%. 
 
Le Thi Mai Hoa24 et al., (2009) developed polymeric drug nanoparticles consist of 
ketoprofen and Eudragit E 100. The morphology structure was done by scanning 
electron microscopy (SEM). The interactions between the drug and polymer can 
identify by Fourier transform Infrared spectroscopy (FTIR). The size distribution was 
measured by means of dynamic Light scattering. The nanoparticles have an average 
size of about 150 nm. The incorporation ability of drugs in the polymeric 
nanoparticles depended on the integration between polymer and drugs well as the 
glass transition temperature of the polymer. 
 
R.Pignatello25 et al., (2002) prepared nanoparticle suspensions from Eudragit RS100 
and RL100 polymer resins and loaded with flurbiprofen, to improve the availability of 
the drug at an intra-ocular level for the prevention of the myosis induced during extra 
capsular cataract surgery. Nanosuspensions were prepared by a quasi-emulsion 
solvent diffusion technique using different formulation parameters (drug to polymer 
ratio, initial polymer concentration, agitation speed). The resulting nanoparticles 
showed mean sizes around 100 nm and a fixed positive charge (x-potential around 
+40/-60 mV). Stability tests after mid time storage (410C or room temperature) or 
freeze-drying was carried out to optimize a possible final pharmaceutical preparation. 
In vitro, dissolution tests showed a controlled release profile of FLU from the 
nanoparticles. In vivo anti-inflammatory efficacy was assessed in the rabbit eye after 
induction of ocular trauma (paracentesis) FLU-loaded nanosuspensions did not show 
toxicity on ocular tissues. Moreover, an inhibition of the miotic response to the 
surgical trauma comparable to a control eye-drop formulation was obtained, even 
though an actual lower concentration of free drug in the conjunctive sac was achieved 
from the nanoparticle system. 
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N. Ubricha26 et al., (2004) evaluated effect of polymers (Eudragit RS or RL) and 
additives within the alcoholic phase (fatty acid esters and polyoxyethylated castor oil) 
on the size, zeta potential and the encapsulation efficiency of the nanoparticles. The 
mean diameter of the various CyA nanoparticles ranged from 170 to 310 nm the size 
as well as the zeta potential increased by adding fatty acid ester and polyoxyethylated 
castor oil within the organic phase. No significant differences in surface potential 
were observed for all formulations tested. Probably due to the very low water 
solubility of the drug, high encapsulation efficiencies were observed in a range from 
70 to 85%. The oral absorption of CyA from these polymeric nanoparticles was 
studied in rabbits and compared to that of neoral capsule. Based on comparison of the 
area under the blood concentration time curve values, the relative bioavailability of 
CyA from each nanoparticulate formulation ranged from 20 to 35%. 
 
Eliza Glowka27et al., (2009) developed and characterized polymeric nanoparticles as 
a sustained release system for salmon calcitonin (sCT) by a double emulsion solvent 
evaporation method using Eudragit RS and two types of a biodegradable poly (lactic-
co-glycolic) copolymer (PLGA). The sCT was incorporated into nanoparticles with 
encapsulation efficiencies in the range 69–83%. In vitro release studies, 
unconventionally conducted in 5% acetic acid, showed great differences in sCT 
release time profiles. Nanoparticles with fast release profile (Eudragit RS, 
PLGA/Eudragit RS) released 80–100% of the encapsulated drug within a few hours. 
In contrast, the sCT release from pure PLGA nanoparticles was very slow, incomplete 
and reached only 20% after 4 weeks. In vivo study, conducted in wistar rats, proved 
that elevated serums CT levels could be sustained for 3 days after subcutaneous 
administration of PLGA nanoparticles and the achieved bioavailability was increased 
compared to sCT solution. 
 
Uracha Ruktanoncha28et al., (2009) developed gamma-oryzanol, an antioxidant, 
was incorporated into three different types of solid lipid wax, triglycerides, a mixture 
of glycerides as solid lipid nanoparticles (SLN) and liquid lipid as nanoemulsion 
(NE). Instability was found only from NE due to its significant increase in particle 
size and decreased entrapment efficiency at a storage temperature of 450C. Solid lipid 
type in SLN plays an important role on % entrapment efficiency, but not chemical 
stability. A decrease in crystallinity of SLN was observed with the incorporation of 
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gamma oryzanol and low recrystallization index were found with two glycerides-
based SLN. The in vitro release studies demonstrated that a biphasic release pattern 
fitted well with the Higuchi model of SLN formulations. In comparison, nearly 
constant release was observed in NE comprised of similar composition. Wax-based 
SLN demonstrated the lowest cytotoxicity NE, wax-based SLN and a mixture of 
glycerides based SLN were considered to enhance the antioxidant activity of gamma 
oryzanol. 
 
SelvakumarKalimuthu29 et al., (2009) prepared nanoparticles of Carvedilol with 
Eudragit E 100 were prepared by the nanoprecipitation method using polymeric 
stabilizer Poloxamer 407. Nanoparticles of Carvedilol were obtained with high 
encapsulation efficiency. The particles were characterized for particle size by photon 
correlation spectroscopy and transmission electron microscopy. The in vitro release 
studies were carried out by USP Type II apparatus in SGF without enzyme (pH 1.2). 
The particle size of the prepared nanoparticles ranged from 190 nm – 270 nm. 
Nanoparicles of Carvedilol were obtained with high encapsulation efficiency (85-
91%). The drug release from the carvedilol nanoparticles showed within 5 minutes. 
These studies suggest that the feasibility of formulating carvedilol loaded Eudragit E 
100 nanoparticles for the treatment of hypertension. 
 
Rosario Pignatello30 et al., (2002) prepared nanoparticles by nanopreciptation and 
modification of the quasi-emulsion solvent diffusion technique using variable 
formulation parameters (drug to polymer ratio, total drug and polymer amount, 
stirring speed). Nanosuspensions had mean sizes around 100 nm and a positive charge 
(z-potential of 140/160 mV), this makes them suitable for ophthalmic applications. 
Stability tests (up to 24 months storage at 480C at room temperature) or freeze-drying 
were carried out to optimize a suitable pharmaceutical preparation. In vitro dissolution 
tests indicated a controlled release profile of ibuprofen from nanoparticles. In vivo 
efficacy was assessed on the rabbit eye after induction of an ocular trauma 
(paracentesis). An inhibition of the miotic response to the surgical trauma was 
achieved, comparable to a control aqueous eye-drop formulation, even though a lower 
concentration of free drug in the conjunctive sac was reached from the nanoparticle 
system. Drug levels in the aqueous humor were also higher after application of the 
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nanosuspensions moreover Ibuprofen-loaded nanosuspensions did not show toxicity 
on ocular tissues. 
 
C. Schwarz31 et al., (1994) developed (SL) nanoparticles by high pressure 
homogenization of a melted lipid (Dynasan I 12) dispersed in water at increased 
temperature (70°C). Soy lecithin and poloxamer 188 were used as surfactants and 
stabilizers of the particles. The effect of homogenization parameters (pressure, cycle 
number) was studied and optimized to yield solid lipid nanoparticles of a quality 
suitable for intravenous injection. Particles were characterized by photon correlation 
spectroscopy (PCS) and zeta potential measurements, the fraction of large particles 
being the limiting factor for intravenous injection was determined using a Coulter 
Counter. The optimum formulation was suitable for intravenous injection (monograph 
‘Particulate Matter’, USP XXII).  
 
Zih-rou HUANG132 et al., (2008) developed Compritol (SLN-C), Precirol squalene 
(nano structured lipid carriers; NLC), and squalene as the lipid core material. These 
systems were assessed and compared by evaluating the mean diameter, surface 
charge, molecular environment, camptothec in release, and cell viability against a 
melanoma. The safety and storage stability of these systems were also preliminarily 
examined. The particle size ranged from 190 to 310 nm, with the NLC and LE 
showing the smallest and largest sizes, respectively. The in vitro drug release occurred 
in a sustained manner in decreasing order. It was found that varying the type of inner 
phase had profound effects on cell viability. The SLN-P generally showed higher 
cytotoxicity than the free control. The treatment of melanomas with the camptothecin-
loaded SLN-C and NLC yielded cytotoxicity comparable to that of the free form. The 
percentage of erythrocyte hemolysis by all nanoparticles was ≤ 5%, suggesting a good 
tolerance to lipid nanoparticles. The results collectively suggest that the SLN-P may 
have the potential to serve as a delivery system for parenteral camptothecin 
administration because of the sustained drug release, strong cytotoxicity, limited 
hemolysis and good storage stability. 
 
Swarnali Das33 et al., (2010) prepared positively charged amphotericin-B loaded 
nanoparticles providing a controlled release formulation. The particles were prepared 
by solvent displacement or nanoprecipitation method. The non-biodegradable 
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positively charged polymer Eudragit RL 100 was used to prepare the different 
formulations with varying ratios of drug and polymer. The formulations were 
evaluated in terms of particle size, zeta potential, and differential scanning 
calorimetry measurements. Drug entrapment and release properties were examined 
also. The antimicrobial activity against Fusariumsolani was determined. In vivo eye 
irritation study was carried out by a modified Draize test. All the formulations 
remained within a size range of 130 to 300 nm in fresh preparation as well as after 2 
months. The zeta potential was positive (+22 to -42 mV) for all the formulations were 
suitable for ophthalmic application. A prolonged drug release was shown by all the 
formulations. The formulation possesses a good antifungal activity against 
Fusariumsolani when tested by disk diffusion method, and no eye irritation on in vivo 
testing was found. 
 
Umasankar34 et al., (2010) developed flutamide nanoparticles by nanoprecipitation 
method. Using Euragit (RL100) as a copolymer with various different ratio 
nanoparticles were characterized by determining its particle size, drug entrapment 
efficiency drug release and stability studies. The particle size ranged between 335 nm 
to 620 nm. Drug content was found of the supportive to drug release pattern. The in 
vitro release of flutamide nanoparticles were carried out which exhibited sustained 
release of flutamide from nanoparticles up to 16 hrs. 
 
Ahmed H. Elshafeey35 et al., (2010) prepared Acyclovir (ACV) Eudragit (EUD) 
nanoparticles (NPs) different charge density. The effect of charge intensity on particle 
size, encapsulation efficiency and in vitro dissolution was assessed. The 
bioavailability of ACV NP colloids were evaluated in human volunteers, compared 
with commercial product using a validated LC–MS/MS method with a lower limit of 
quantification (LLOQ) of 0.02g/ml. EUD RL 100 with higher ammonium groups 
gave smaller NPs than EUD RS 100. The surface charge of the polymer did not affect 
encapsulation efficiency and in vitro dissolution. In human volunteers, both F2 and F5 
colloidal nanosuspensions prepared with EUD RS and RL respectively in drug to 
polymer ratio 1:3 sustained the oral absorption of ACV, expressed by the significant 
lower Cmax, significant delayed Tmax and the significant higher HVD 50% Cmax 
The mean Cmax of F2, F5, and zovirax were 0.61 ± 0.06, 0.73 ± 0.07 and 
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0.92±0.21g/ml respectively. Furthermore AUC0 –12 of F2 and F5 was significantly 
higher than that of zovirax with values of 4.37 ± 0.885.14 ± 0.87 and 3.21 ± 0.53g/ml 
h respectively. The higher AUC0–12 for both F2 and F5 reflected high relative 
bioavailability of 136% and 159% respectively compared to commercial ACV tablets. 
 
Romilamanchanda36 et al., (2010) developed biodegradable poly (DLlacticcoacid) 
(PLGA) nanoparticle simultaneously loaded with indocyanine (ICG) and (DOX). The 
modified oil in water single emulsion evaporation method was used. To enhance the 
incorporation of both agents and control particle size, four independent processing 
parameters including amount of polymer, initial ICG and DOG entrapment in 
nanoparticles as well as the nanoparticles size was determined. The nanoparticles 
produced by standardized formulation were in the ranges of 171±0.0014, n=3.The 
entrapment efficiency was determined by spectrofluorometer measurements. The 
efficiency was 44.4 ± 1.6% for ICG and 74.3 ± 1.9% for DOX. Drug loading 
was1.015 ± 0.001%w/w, for ICG and 0.022 ± 0.001%w/w, for DOX n=3. 
 
AtulGaikwad37 et al., (2010) developed Eudragit RS100 nanoparticles by 
nanoprecipitation method for oral delivery. Formulation were prepared in ten different 
drugs to carrier ratio, and characterized for particle size, shape, percentage yield, drug 
entrapment, stability studies, zeta potential, FT-IR study, in vitro drug release and 
release kinetics. The shape of nanoparticles was found to be spherical by scanning 
electron microscopy studies, whereas size ranging from 163 nm to 378 nm. FTIR 
study confirmed that there was no interaction between drug and polymer. Entrapment 
efficiency was in the range of 14.95 ± 0.06 to 69.73 ± 0.03 W/W. No appreciable 
difference was observed in the extent of degradation of product during 60 days in the 
nanoparticles, which were stored at various temperatures. Zeta potential of 
formulation supports the minimum interaction between the particles. The in vitro drug 
release study revealed that sustained release of some formulation last up to 24 hour. 
The release followed Higuchi kinetics, which indicates diffusion controlled release 
pattern of drug. 
 
Michele Trotta38 et al., (2003) developed nanoparticles based on the emulsification 
of a butyl lactate or benzyl alcohol solution of a solid lipid in an aqueous solution of 
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different emulsifiers, followed by dilution of the emulsion with water, was used to 
prepare glyceryl monostearate nanodispersions with narrow size distribution. To 
increase the lipid load the process was conducted at 47 ± 20C and in order to reach 
submicron size a high-shear homogenizer was used. Particle size of the solid lipid 
nanoparticles (SLN) was affected by using different emulsifiers and different lipid 
loads. By using lecithin and taurodeoxycholic acid sodium salt, on increasing the 
GMS percentage from 2.5 to 10% an increase of the mean diameter from 205 to 695 
nm and from 320 to 368 nm was observed for the SLN prepared using benzyl alcohol 
and butyl lactate, respectively. Transmission electron micrographs of SLN reveal 
nanospheres with a smooth surface. 
 
Roberta CavalliTrotta39 et al., (1997) prepared (SLN) from three oil in water 
microemulsions, whose internal phase was constituted of different lipid matrices. The 
dispersion media were two aqueous solutions of trehalose and PluronicF68 at 2% 
besides distilled water. SLN were sterilized by autoclaving, were stable during 
sterilization and maintained a spherical shape and narrow size distribution as 
confirmed by TEM analysis. SLN dispersions in water did not present nanoparticles 
larger than 1m after storage at 4°C for 1 year they were freeze dried after sterilization 
to obtain dry products.  
 
Vandervoort40 et al., (2004) developed PLGA nanoparticles were prepared by 
nanoprecipitation method. Different stabilizers, polyvinyl alcohol (PVA), carbopol 
and Poloxamer are used. The influence of the homogenized pressure and number of 
cycles on the properties of nanoparticles were studied. Particle size was shown to 
depend on the stabilizer used. An increase of the homogenization pressure or the 
number of cycles resulted in a decrease in particle size. The zeta potential value was 
influenced mainly by the nature of the stabilizer. Particles stabilized with poloxamer 
or PVA showed a slightly negative zeta potential value, while samples stabilized with 
carbopol possessed a more negative zeta potential, which become less negative after 
homogenization. Drug encapsulation depended strongly on the stabilizer used. The 
higher drug entrapment of the carbopol-stabilized particles could be explained by an 
electrostatic interaction between the negatively charged carboxyl groups of carbopol 
and the positively charged, protonated pilocarpine. The drug release patterns of the 
particles prepared were quite similar. Differences between the releases patterns of the 
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homogenized particles could be attributed both to differences in size as well as drug 
encapsulation. Turbidimetric measurements suggested an interaction between mucin 
and PLGA nanoparticles exclusively stabilized with Carbopol. 
 
Rosario Pignatello41 et al., (2006) developed AD6-loaded polymeric nanoparticle 
suspensions were made using inert polymer resins (Eudragit RS100 and RL100). By 
modified the quasi-emulsion solvent diffusion technique the chemical stability of 
AD6 in the nanosuspensions was assessed by preparing some formulations using 
(unbuffered) isotonic saline or a pH 7 phosphate buffer solution as the dispersing 
medium. The formulations were stored at 4°C, and the rate of degradation of AD6 
was followed by high performance liquid chromatography (HPLC). The obtained 
nanosuspensions showed mean sizes and a positive surface charge (ζ-potential) that 
makes them suitable for an ophthalmic application these properties were maintained 
upon storage at 4°C for several months. In vitro dissolution tests confirmed a 
modified release of the drug from the polymer matrixes. Nanosuspensions prepared 
with saline solution and no or lower amounts of surfactant (Tween 80) showed an 
enhanced stability of the ester drug for several months, with respect to an AD6 
aqueous solution. Based on the technological results, AD6-loaded Eudragit retard 
nanoparticle suspensions appear to offer promise as a means to improving the shelf 
life and bioavailability of this drug after ophthalmic application. 
 
Rubiana Mara Mainardesa42 et al., (2010) prepared nanoparticles were 
characterized in terms of size, zeta potential, morphology and drug entrapment 
efficiency. The results showed that although PLA and blend nanoparticles had the 
same morphology, the particle size and zeta potential were changed by the PEG. The 
drug entrapment efficiency was increased by PEG presence. The pharmacokinetic 
study showed that all the nanoparticles were able to sustain zidovudine delivery over 
time, but greater efficiency was obtained with PLA–PEG blend nanoparticles whose 
Tmax was twice that of PLA nanoparticles. The PLA and PLA–PEG nanoparticles 
formulations increased the zidovudine mean half-life by approximately 5.5 and 7 h, 
respectively, compared to zidovudine aqueous solution. The relative bioavailability of 
zidovudine-loaded PLA–PEG blend nanoparticles was 2.7, relative to zidovudine-
loaded PLA nanoparticles and 1.3 relative to aqueous solution formulation. Thus, the 
PLA nanoparticles were unable to increase the zidovudine bioavailability compared to 
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aqueous solution formulation. The results obtained in this study indicate the potential 
of the PLA–PEG blend nanoparticles as carriers for zidovudine delivery by the 
intranasal route. 
 
ParthaSaha43 et al., (2010) prepared nanoparticles by ionic gelation method with the 
aid of sonication. Parameters such as the zeta potential, polydispersity, particle size, 
entrapment efficiency and in vitro drug release of the nanoparticles were assessed for 
optimization. The antibacterial properties of the nanoparticle formulation were 
evaluated and compared with that of a commercial formulation Scanning electron 
microscopy revealed that the nanoparticles were in the nano size range but irregular in 
shape. Concentrations of 0.35% w/v of chitosan and 0.40% w/v sodium 
tripolyphosphate (TPP) and a sonication time of 20 min constituted the optimum 
conditions for the preparation of nanoparticles. In vitro release data showed an initial 
burst followed by slow sustained drug release. Then nanoparticles demonstrated 
superior antimicrobial activity to plain nanoparticles and the reference, due probably 
to the synergistic effect of chitosan and ampicillin trihydrate. Modified ionic gelation 
method can be utilized for the development of chitosan nanoparticles of ampicillin 
trihydrate. Polymer and cross linking agent concentrations and sonication time are 
rate-limiting factors for the development of the optimized formulation. The chitosan 
nanoparticles developed would be sustained delivery of ampicillin trihydrate. 
 
UgoBilati44 et al., (2004) processed modifications to improve the versatility of the 
nanoprecipitation technique, particularly with respect to the encapsulation of 
hydrophilic drugs (e.g. proteins). Selected parameters of the nanoprecipitation 
method, such as the solvent and the non-solvent nature, the solvent/non-solvent 
volume ratio and the polymer concentration, were varied so as to obtain polymeric 
nano-carriers. Surfactants added to the dispersing medium were usually unnecessary 
for final suspension stabilization. Changing the solvent/non-solvent volume ratio was 
also not a determinant factor for nanoparticle formation and their final characteristics, 
provided that the final mixture itself did not become a solvent for the polymer. The 
nanoparticles obtained ranged from about 85–560 nm in size. The nanoparticle 
recovery step however needs further improvements, since bridges between particles 
which cause flocculation could be observed. The nanoprecipitation technique is more 
versatile and flexible than previously thought and that a wide range of parameters can 
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be modified. 
 
Angela Lopedota45 et al., (2009) developed glutathione (GSH) by quasi-emulsion 
solvent diffusion technique. The nanoparticles prepared showed homogeneous size 
distribution, mean diameters between 99 and 156 nm, a positive net charge and 
spherical morphology. Solid state FT-IR, thermal analysis (DSC), and X-ray 
diffraction studies suggest that the nanoencapsulation process produces a marked 
decrease in crystallinity of GSH. There results indicate that mean diameters, surface 
charges and drug-loaded nanoparticles were not markedly affected by the CD, 
whereas the presence of the latter influences drug release and to some extent peptide 
stability and absorption. Finally, it has been shown that CD/Eudragit RS 100 NPs may 
be used for transmucosal absorption of GSH without any cytotoxicity using the 
epithelial human HaCaT and murine monocyte macrophage RAW264.7 cell lines. 
 
Yung-ChihKuo46 et al., (2010) investigated on loading efficiency (LE) of stavudine 
(D4T), a human immune deficiency antiretroviral agent, on the external surfaces of 
poly- butyl cyano acrylate (PBCA) and methylmethacrylate, sulfopropylmethacrylate 
(MMA-SPM). The biodegradable PBCA NPs and MMASPM copolymer NPs were 
synthesized, respectively, by emulsion poly-merization and free radical 
polymerization larger polymeric nanoparticles (NPs), the smaller LE of D4T on the 
two kinds of biomaterials. Freeze drying of the two NPs, however, yields an increase 
in particle size and an increase in LE of D4T. These outcomes imply that for oral 
administration, D4T-loaded MMA-SPM NPs may be more advantageous than D4T-
loaded PBCA NPs, and D4T-loaded PBCA NPs may be more favorable than D4T-
loaded MMA-SPM NPs for intravenous injection.  
.
 
K.Derakhshandeh47 et al., (2007) prepared (PLGA) nanoparticles by 
nanoprecipitation method and characterization. The full factorial experimental design 
was used to study the influence of four different independent variables on response of 
nanoparticle drug loading. Analysis of variance (ANOVA) was used to evaluate 
optimized conditions for the preparation of nanoparticles. The physical characteristics 
of PLGA nanoparticles were evaluated using particle size analyzer, scanning electron 
microscopy, differential scanning calorimetry and X-ray diffractometry. The results of 
optimized formulations showed a narrow size distribution with a polydispersity index 
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of 0.01%, an average diameter of 207 ± 26 nm, and a drug loading of more than 30%. 
The in vitro drug release profile showed a sustained 9-NC release up to 160 h 
indicating the suitability of PLGA nanoparticles in controlled 9-NC release. Thus 
prepared nanoparticles described here may be of clinical importance in both 
stabilizing and delivering camptothecins for cancer treatment. 
 
Junping Wanga48 et al., (2010) prepared cationic PLA based nanoparticles  by the 
nanoprecipitation method and solvent evaporation method with polyethylenimine 
(PEI) and chitosan as two types of surface coating materials. Cationic poly(d,l-lactide-
co-glycolide) (PLGA)–PEI, PLGA–chitosan and methoxy poly (ethylene glycol)–poly 
(lactide) (PEG)–PLA/PEI, PEG–PLA–chitosan nanoparticles were characterized in 
terms of size and size distribution by laser scattering, surface charge by zeta potential 
measurement, and surface chemistry by X-ray electron spectroscopy (XPS). The four 
type  nanoparticles were compared for their interaction with RNA and nanoparticles 
mediated RNA transfection efficiency with a hepatitis B model, where the inhibition 
effects of the double strand RNA (RNA) mediated by the four types of nanoparticles 
were evaluated by measuring the HBs Ag expression level. The highest inhibition 
effect of HBs Ag (surface antigen of the hepatitis B Virus (HBV), which indicates 
current hepatitis B infection) expression was achieved by the PEG–PLA–PEI 
nanoparticles mediated RNA transfection. The results demonstrated that the RNA 
delivery follows a size and surface charged manner. 
 
Tao Zhang49 et al., (2011) prepared nanoparticles by emulsification diffusion, their 
size, encapsulation efficiency (EE%), drug release profile, morphology, and 
cytotoxicity are characterized by dynamic light scattering, spectrophotometry, 
transmission electron microscopy, and cellular viability assay/transepithelial electrical 
resistance measurement, respectively. Cellular uptake was elucidated by fluorescence 
spectroscopy and confocal microscopy. The NPs have an average size of 250 nm, 
maximal EE% of 16.1% and 37.2% for TNF and TDF, respectively. There is a 4-fold 
increase in the drug release rate from the 75% S-100 blend in the presence of SFS 
over 72 h. At a concentration up to 10 mg/ml, the PLGA/S-100 NPs are noncytotoxic 
for 48 h to vaginal endocervical/epithelial cells and Lactobacillus crispatus. The 
particle uptake (50% in 24 h) by these vaginal cell lines mostly occurred through 
caveolin-mediated pathway. These data suggest the promise of using PLGA/S-100 
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NPs as an alternative controlled drug delivery system in intra vaginal delivery of an 
anti-HIV/AIDS microbicide. 
 
T. Vetrichelvan50 et al., (2011) prepared alginate nanoparticles by in situ nano 
emulsion polymer cross linking approach. The nano particles were prepared using 
different ratios of alginates and abacavir sulfate in the ratios of (1:1, 1:2 and 1:3). The 
encapsulation efficiency was also studied to find out the percentage drug entrapped in 
the prepared nanoparticles. The result of ratio 1:3 showed a good encapsulation 
efficiency of 98.71%. Abacavir sulfate nanoparticle was confirmed by FT-IR, DSC 
and quantitated by uv prepared nanoparticle appeared spherical with a dense drug core 
in transmission electron microscopy studies. Hydro dynamic diameter of 
nanoparticles was 63 ± 0.235 nm, with a Gaussian distribution and the zeta potential –
0.6. Sustained diffusive drug release was observed in vitro, following zero order 
Kinetics releasing the drug pay load over a period of 16h. Embedding abacavir sulfate 
in alginate provided sustained release. They also offered better pharmacokinetic 
properties to the drug than that afforded by the free drug itself. The nanoparticle 
technique developed can be a good choice for the development of sustained 
antiretroviral drug carrier. 
 
Kathleen Dillen51 et al., (2008) prepared nanoparticles by w/o/w emulsification 
solvent evaporation. Particle size and zeta potential of the nanoparticles were 
measured. Nanoparticles were incubated for a short time with P. aeruginosa and S. 
aureus followed by measurement of the size of nanoparticles and of P. aeruginosa 
and S. aureus with and without adherent nanoparticles. Flow cytometric 
measurements were performed to detect the attachment of particles to 
microorganisms. Eudragit containing nanoparticles possessed a positive zeta potential, 
while PLGA nanoparticles were negatively charged. Following adsorption of Eudragit 
containing nanoparticles, a size increase for P. aeruginosa was observed. Flow 
cytometric analyses confirmed that Eudragit containing particles showed stronger 
interactions with the test organisms than PLGA nanoparticles. Adhesion of particles 
was more pronounced for P.aeruginosa than for S.aureus. Cationic Eudragit 
containing nanoparticles showed better adhesion to microorganisms than anionic 
PLGA nanoparticles, which is probably due to enhanced electrostatic interactions. 
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N.Jawahar52 et al., (2009) prepared Poly (D, L-Lactide-co-Glycolide) (PLGA) 
nanoparticles by nanoprecipitation method using tribloere polymeric stabilizer 
(Pluronic RF-68). The particles were characterized for drug content, particle size and 
particle morphology by Transmission electron microscope (TEM). In vitro studies 
were determined by the bulk equilibrium reverse dialysis bag technique. The particle 
size of the prepared nanoparticles ranged from 20 nm to 340 nm. nanoparticles of 
ramipril were obtained with high encapsulation efficiency (68-75%). The drug release 
from the ramipril nanoparticles was sustained in Batch (F3) for more than 24 hrs with 
72% drug release. This study suggests that the feasibility of formulating Ramipril 
loaded PLGA nanoparticles can be used to improve the therapeutic efficacy of 
Ramipril in the treatment of hypertensive disorder. 
 
Jasvinder Singh53 et al., (2006) prepared nanoparticles by water-in-oil in- water 
(w/o/w) double emulsion solvent evaporation method, demonstrated release proWles 
which were dependent on the properties of the polymers. An in vitro experiment using 
Caco-2 cells showed signi Wcantly higher uptake of PCL nanoparticles in comparison 
to polymeric PLGA, the PLGA–PCL blend and co-polymer nanoparticles. The 
highest uptake mediated by the most hydrophobic nanoparticles using Caco-2 cells 
was mirrored in the in vivo studies following nasal administration. PCL nanoparticles 
induced DT serum speciWc IgG antibody responses signiWcantly higher than PLGA. 
A signi Wcant positive correlation between hydrophobicity of the nanoparticles and 
the immune response was observed following intramuscular administration. The 
positive correlation between hydrophobicity of the nanoparticles and serum DT 
speciWc IgG antibody response was also observed after intranasal administration of 
the nanoparticles. The cytokine assays showed that the serum IgG antibody response 
induced is diVerent according to the route of administration, indicated by the 
diVerential levels of IL-6 and IFN. The nanoparticles eliciting the highest IgG 
antibody response did not necessarily elicit the highest levels of the cytokines IL-6 
and IFN. 
 
Liang wang54 et al., (2006) prepared nanoparticles by melt mixing method with 
hydrophilic silica particles (Aerosil and Sylysia) with different particle size and 
specific surface areas as carriers. Powder X-ray diffraction and differential scanning 
                                                                           
LITERATURE REVIEW 
 
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai. Page 43 
 
calorimetry evaluation showed that NTD in the SDs treated with the melt-mixing 
method was dispersed in the amorphous state. FT-IR spectroscopy obtained with the 
SDs indicated the presence of hydrogen bonding between the secondary amine groups 
of NTD and silanol groups of silica particles. The dissolution property of NTD in the 
SDs was remarkably improved regardless of the grade of silica. At the end of the 
dissolution test (60 min) the concentrations of NTD for the SDs with Aerosil 200 and 
Sylysia 350 were 8.88 and 10.09m g/ml, corresponding to 28 and 31 times that of the 
original NTD crystals, respectively. The specific surface area and the adsorbed water 
amount of the SDs were also significantly improved. The rapid dissolution rate from 
the SDs was attributed to the amorphization of drug, improved specific surface area 
and wet ability than the original drug crystals. In the stability test, powder X-ray 
diffraction pattern indicated that amorphous NTD in the SD with aerosil 200 was 
stable for at least 1 month under the humidy conditions (40 °C/75% RH). 
 
S. Ramesh55 et al., (2010) prepared nanoparticles by controlled gel-lification process. 
In this research work, different drug and polymer ratios were used. The prepared 
nanoparticles were evaluated to assess the various parameters such as drug content 
analysis, particle size analysis (SEM Analy-sis), Zeta potential analysis, In Vitro drug 
release and stability studies. The particle size of prepared nanoparticles was found to 
be 500nm. The drug content analysis of all the prepared formulations was estimated in 
the range of 57.34 ± 0.10 to 65.33 ± 0.11 %. The zeta potential of the sepia 
nanoparticles was estimated as 69mv. The Cumulative percentage drug release of the 
third formulation was found to be 90.36 %. By observing the in vitro drug release 
results of all formulation, we concluded that, AMN3 formulation was found to be best 
formulation with higher Cumulative percentage drug release. 
 
Adlin jino nesalin j56 et al., (2009) prepared Flutamide nanoparticles by ionic 
gelation technique. Nanoparticles of different core: coat ratio were formulated and 
analyzed for total drug content, loading efficiency, particle size and in vitro drug 
release studies. From the drug release studies it was observed that nanoparticles 
prepared with chitosan in the core: coat ratio 1:4 gives better sustained release for 
about 12 hrs as compared to other formulations. 
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J. Vandervoort57 et al., (2002) prepared nanoparticles by w/o/w emulsification 
solvent evaporation method. In most cases poly (vinyl alcohol) (PVA) is used as 
stabilizer of the emulsion. The goal of this study was to compare a series of polymers 
to PVA in a 22 full factorial design study. The influence of the concentration of PVA 
And the polymers tested on particle size and zeta potential value was evaluated before 
and after freeze-drying of the prepared particles. Nanoparticles were obtained with 
most polymers when they were used in combination with PVA. Leaving PVA out of 
the formulation, however, increased the size of the particles over 1m. Two exceptions 
are poloxamer and carbopol, which can be considered as valuable alternatives to 
PVA. Zeta potential values were usually slightly negative; the most extreme zeta 
potential values were measured when poloxamer and carbopol were employed. The 
use of gelatin type A made it possible to achieve positive values. The original 22 full 
factorial design study was further expanded to a central composite design for 
poloxamer and carbopol, in order to fit the measured data to a quadratic model and to 
calculate response surfaces. 
 
Manish k gupta58 et al., (2009) prepared Cyclosporine (CYA) loaded Eudragit 
RL100 nanoparticles by solvent evaporation technique, with 2% PVA as stabilizer. 
Four batches of nanoparticles with varying drug concentrations (CYN-1, CYN-2, 
CYN-3 and CYN-4) were prepared. Cumulative % drug release of formulations CYN-
1, CYN-2, CYN-3 and CYN-4 was 94.35%, 93.89%, 88.28% and 85.36% 
respectively. Formulation CYN-2, which proved to be the best showed a mean 
particle size of 236 nm and entrapment efficiency of 58.27%. The in vivo result of 
formulation CYN-2 revealed that the drug loaded nanoparticles showed preferential 
drug targeting to liver followed by spleen, lungs and kidneys. Stability studies showed 
that maximum drug content and closest in vitro release to initial data was found in the 
sample (formulation CYN-2) stored at 40C. So, in the present study Cyclosporine 
loaded Eudragit Nanoparticles were prepared and targeted to various organs to a 
satisfactory level and the prepared nanoparticles were stable at 40C. 
 
Swarnali Das59 et al., (2011) prepared AmB-loaded Eudragit nanoparticles by A 
solvent displacement technique. These NPs had a mean size range of 150–290 nm and 
a zeta potential of +19–28 mV. Even after 6 months of stability study, results were 
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unchanged, indicating the good potential for ocular application. In vitro release 
studies revealed that a maximum amount of drug was released within 24 hours (60%). 
The results obtained from microbial assay showed that the antifungal activity of drug-
loaded NPs was equal to or slightly lower than that of free-AmB solution. In vivo 
experiments showed that, following topical instillation of nanosuspension to a rabbit's 
eye there was no irritation. From these results we can conclude that Eudragit RS 100 
nanosuspension may represent an efficacious vehicle to deliver the drug into the eye. 
 
Francesco Castelli60 et al., (2003) prepared Nanosuspensions by a modification of 
the quasi-emulsion solvent diffusion technique (QESD), a particular approach to the 
general solvent-change method. This kind of system was planned for the ophthalmic 
release of non-steroidal anti-inflammatory drugs in ocular diseases associated with 
inflammatory processes (i.e. post-cataract surgery or uveitis). The drug release was 
monitored by differential scanning calorimetry (DSC), following the effects exerted 
by IBU on the thermotropic behaviour of DMPC multilamellar vesicles. IBU affects 
the main transition temperature (Tm) of phospholipid vesicles, causing a shift towards 
lower values, driven by the drug fraction entering the lipid bilayer. The obtained 
values have been used as a calibration curve. DSC was performed on suspensions of 
blank liposomes added to fixed amounts of unloaded and IBU-loaded Eudragit RS100 
and RL100 nanosuspensions as well as to powdered free drug. The Tm shifts caused 
by the drug released from the polymer system or by the free drug, during incubation 
cycles at 37 ◦C, were compared to the calibration curve in order to obtain the fraction 
of drug released. The results were also compared with in vitro dialysis release 
experiments. The suitability of the two different techniques to follow the drug release 
as well as the differences between the RL and RS polymer systems was compared, 
confirming the efficacy of DSC for studying the release from polymer nanoparticulate 
systems. Explanation of the different rate of kinetic release could be due to void 
liposomes, which represent a better up-taking system than the aqueous solution phase 
in the dialysis experiments. 
 
Cunxian Song61 et al., (1998) prepared nanoparticles by oil–water emulsions using 
biodegradable polymers such as poly (lactic acid–co-glycolic acid) (PLGA), and 
specific additives after particle formation, to enhance arterial retention using either 
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heparin, didodecylmethylammonium bromide (DMAB), or fibrinogen, or 
combinations. Femoral and carotid arteries of male mongrel dogs were isolated in 
situ, and were then subjected to a balloon angioplasty. A NP suspension of a 
predetermined concentration was then infused into the artery for various durations. 
This was followed by a 30 min restoration of blood flow through the vessel. The 
arterial segments were excised and analyzed for drug levels. From the drug loading of 
the NP and the drug levels in the artery, the quantity of nanoparticles retained was 
calculated and expressed as mg per 10 mg dry arteries. In general, repeated short 
infusions of nanoparticle suspension (15 s34) were two-fold more effective in terms 
of higher arterial U-86 levels than a single prolonged infusion (60 s). A single 15 s 
infusion was not significantly different than a 60 s infusion on NP arterial uptake. NPs 
modified with either DMAB or fibrinogen had about 2.5-fold higher uptake levels 
compared to non-modified NPs (39.262.5 and 49.162.4 vs. 21.560.6, mg/10 mg 
mean6s.e. respectively). A comparably enhanced NP uptake was noted with a 
combined heparin /DMAB modification. Increasing the concentration of NP in 21 
infusate from 5 to 30 mg ml significantly increased arterial NP uptake level (from 
22.563.5 to 83.761.4 mg/10 mg). Thus, the results support the view that modified 
nanoparticles along with optimized infusion conditions could enhance arterial wall 
drug concentrations of agents to treat restenosis. 
 
Yadav SC62 et al., (2002) investigated on Biodegradable polymeric nanoparticles 
based drug delivery systems Nanoparticulate drug delivery systems seem to be a 
viable and promising strategy for the biopharmaceutical industry. They have 
advantages over conventional drug delivery systems. They can increase the 
bioavailability, solubility and permeability of many potent drugs which are otherwise 
difficult to deliver orally. Nanoparticulate drug delivery systems will also reduce the 
drug dosage frequency and will increase the patient compliance. In near future 
nanoparticulate drug delivery systems can be used for exploiting many biological 
drugs which have poor aqueous solubility, permeability and less bioavailability. 
nanoparticles provide ingenious treatment by enabling targeted delivery and con- 
trolled release. 
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M Sivabalan63 et al., (2004) formulated and evaluated 5-Fluorouracil loaded 
Chitosan and Eudragit Nanoparticles for Cancer therapy. The goal of the investigation 
was to formulate and evaluate chitosan and Eudragit nanoparticles of 5- Fluorouracil 
for cancer therapy. Nanoparticles of 5- Fluorouracil were prepared using chitosan, 
Eudragit S 100, liquid paraffin and Tween -20 using Emulsion droplet coalescence 
method. The nanoparticles prepared were evaluated for morphology, loading 
efficiency, in vitro release and in vitro anticancer activities.  The formulations CF1, 
CF2, EF2 and EF3 showed good drug release from the polymer.  Among the four 
formulations EF 2 (1% Chitosan & 1.5 % Eudragit S 100) showed maximum drug 
release in 12 hours diffusion study and good entrapment efficiency. In vitro anticancer 
study revealed that the formulated nanoparticles were found to have good cidal 
activity on cancer cells in sustained manner. 
 
Bivash Mandal64 et al., (2010) prepared Sulfacetamide loaded polymeric 
nanosuspension by the solvent displacement method using acetone and 1% (w/v) 
Pluronic F108 solution. Drug to polymer ratio was chosen at four levels: 10/100 (B1), 
20/100 (B2), 30/100 (B3), 40/100 (B4) (by weight). Characterization of 
nanosupension was performed by measuring particle size, zeta potential, Fourier 
Transform infrared spectra (FTIR), Differential Scanning Calorimetry (DSC), Powder 
X-Ray Diffraction (PXRD), drug entrapment efficiency and in vitro release. In 
addition, freeze drying, redispersibility and short term stability study at room 
temperature and at 400C were performed. Spherical, uniform iv particles (size below 
500 nm) with polydispersity index range of 0.414 to 0.67 and positive zeta potential 
were obtained. Positive surface charge can allow a longer residence time of 
nanoparticles on the cornea surface, with a consequence slower drug release and 
higher drug concentrations in the aqueous humor, compared to classical eye drop. No 
significant drug polymer interaction was observed in the solid state characterization of 
freeze dried nanosuspension using DSC, PXRD, and FTIR. Drug entrapment 
efficiency was found to be in the range of about 28% to about 35%. In order to 
increase drug entrapment efficiency, selected batch was chosen to study the effect of 
changing polymer content, pH of external media and incorporation of polymethyl 
methacrylate (PMMA) on drug entrapment efficiency. Changing the external phase 
pH and incorporation of PMMA were significantly increased drug entrapment 
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efficiency of nanoparticles. No significant change in average particle size was 
observed after storage at room temperature and at 4ºC. Freeze dried nanosuspesnions 
were easily redispersed after manual hand shaking. Both batch of B3 containing 5% 
sucrose and 5% mannitol as cryoprotectant exhibited good redispersibility in water. 
The formulation of Sulfacetamide in Eudragit RL 100 nanosuspension could be 
utilized as potential delivery system for treating ocular bacterial infections. 
 
Saikat Das65 et al., (2005) prepared aspirin loaded albumin nanoparticles by 
coacervation method. Aspirin is a common anti-inflammatory and anti platelet agent 
widely used for various conditions. Albumin being both bioacceptable and 
biodegradable has a distinct advantage as a vehicle of drug delivery. By varying 
aspirin albumin ratios from 0.06 to 1.0 obtained stable nanoparticles of sizes 46.8 nm 
to 190.8 nm respectively with low polydispersity. Photon Correlation Spectroscopy 
(PCS) and Transmission Electron Microscopy (TEM) of the samples were done to 
characterize the nanoparticles. Drug encapsulation measured by UV spectroscopy 
varied from 30% to 80% for different ratios of aspirin: albumin. In vitro release study 
was conducted across a Spectrapor-membrane (cut off 3500 Da) precluding albumin. 
In contrast to simple drug solution, whose concentration peaks with in ½ to 1 hour, 
nanoparticle formulation releases aspirin at a sustained rate for prolonged duration 
(50% total cumulative percentage at the end of 20 hours, 90% at 72 hrs). From the 
above results we can conclude that coacervation method is well suited to produce 
albumin nanoparticles and the preparative variables of the procedure can be fine tuned 
depending on the clinical application. Nanoparticles thus produced, can be applied for 
intra-articular therapy in arthritis or as intraocular release agents for diabetic 
retinopathy. 
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3. AIM OF PRESENT WORK 
         Selective drug delivery systems or targeted drug delivery systems are designed 
to improve the benefit/risk ratio of any drug. They make the drug available more in 
the required tissue by decreasing its distribution in unwanted tissues. Innovations in 
the field of nanotechnology further fuel the research for the development of newer 
targeted drug release system which desired concentration of drug at the vicinity of 
action in a controlled drug release rate. 
  
          The present study was aimed to development and characterization of 
Lamivudine loaded nanoparticles drug delivery system using bio-degradable polymer 
such as Eudragit RS100 & Eudragit RL 100. The polymer enhances the binding of 
Lamivudine nanoparticles in specific (or) targeted site with sustained release of drug 
increasing therapeutic efficacy. 
 
Lamivudine is analogue of cytidine. It inhibit both type (1 and 2) of HIV 
reverse transcriptase and also the reverse transcriptase of hepatitis B. Currently 
available dosage forms shows some side effect like abdominal pain, muscles pain, 
headache, fever, rash, alopecia, cough, nasal symptoms, arthralgia, most of which are 
dose dependent. 
 
Thus the present work Development and characterization of nanoparticulate 
drug delivery system of antiviral drug Lamivudine aims; 
 
 To overcome variable systemic availability. 
 To overcome side effect. 
 To overcome the drug resistance on long term. 
 Specific site drug delivery at controlled rate. 
 Prolonged systemic circulation. 
 
 
 
 
PLAN OF WORK  
 
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai. Page 50 
 
 
 
PLAN AND SCOPE OF WORK 
 
 Plan of the present work involves the following process:  
 
• Preformulation studies involve observation of physical and chemical data 
available. The identification of raw materials and compatibility studies between 
drug and polymer to be done by using Infrared spectrophotometry.  
 
• Preparation of Lamivudine loaded Eudragit RS100 & Eudragit RL100 
nanoparticles can be prepared by Emulsion solvent evaporation method. 
 
• Formulation of Lamivudine loaded nanoparticle in various ratios of drug and 
polymer.  
 
  The best formulation will be selected based on the results of following 
parameters. The prepared nanoparticle can be evaluated by following chemical 
characteristic: 
 
• Drug content determination. 
 
• Drug entrapment efficiency. 
 
• In vitro drug release of formulated nanoparticles. 
 
• The morphology of nanoparticle was examined by scanning electron microscopy 
(SEM) 
 
• Zeta potential analysis of the optimized formulation  
 
• Sterilization of optimized nanoparticle formulation by Membrane Filtration 
method. 
 
• Sterility test for the formulation to ensure the success of sterilization process. 
 
• Stability studies for the best formulation at different temperature. 
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5. METHODOLOGY 
 
5.1. INSTRUMENTS AND MATERIALS USED 
 
Table: 6: Instruments used 
 
S. 
No 
 
EQUIPMENTS 
 
SOURCE 
  1. Vortex Mixer Remi motors Ltd, Mumbai. 
  2. Rotary flash evaporator Equitron, Mumbai. 
3. Probe sonicator Bandelin, Germany. 
4. Magnetic stirrer Remi motors Ltd. 
5. Single beam UV spectrophotometer Shimadzu corporation, Japan. 
6. Electronic balance Shimadzu. 
7. Stability chamber  Osword, Mumbai. 
8. Ultra certification Remi motors Ltd, Mumbai. 
9. pH – meter ElicoPvt Ltd,Chennai. 
10. FTIR Spectrophotometer Perkin Elmer, Germany. 
11. Autoclave Kemi chem, India 
12. Double beam UV Spectro photometer Perkin Elmer, Germany. 
13.                    Laminar air flow Klenzaids, Mumbai 
14. Incubator M.C.DALAL&CO, Mumbai 
15. Freeze drier Allied frost, Mumbai 
16.  Hot air oven Biochemicals, Mumbai. 
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Table: 7: Materials used 
 
S. 
No 
MATERIALS SUPPLIER 
1. Lamivudine Bafna pharmaceuticals.Mumbai. 
2. Eudragit RS 100 Micro Labs Hosur. 
3. Eudragit RL100 Micro Labs Hosur. 
4. Poly Vinyl Alcohol (PVA) S.D.Fine Chemicals.Ltd ,Boisar 
5. Potassium dihydrogen phosphate S.D.Fine Chemicals. Ltd,Boisar 
6. Sodium chloride S.D.Fine Chemicals. Ltd,Boisar 
7. Disodium hydrogen phosphate S.D.Fine Chemls. Ltd,Boisar 
8. Methanol Merck, India 
  9. 
 
Membrane filter Gotting Ltd, West Germany 
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5.2. DRUG PROFILE 
 
LAMIVUDINE67,68 
(2', 3’-dideoxy-3'-thiacytidine, commonly called 3TC) is a potent nucleoside 
analog reverse transcriptase inhibitor (nRTI) 
 
Chemical Structure: 
                                                                                
Chemical name 
(4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)one. 
 
Molecular formula 
C8H11N3O3S  
 
Molar mass 
229.26 g/mol  
 
Description 
 A white powder. 
 
Melting point 
160◦C–162◦C  
 
Solubility 
Soluble in water, sparingly soluble in methanol, and insoluble in acetone. 
 
 
 DRUG PROFILE 
 
Dept. of Pharmaceutics, K.M. college of Pharmacy, Madurai.  Page 54 
 
Pharmacology 
 Lamivudine was originally developed as an antiretroviral drug. The drug is 
metabolised intracellular to the active triphosphate moiety by infected by both infected 
and uninfected cells. Triphosphate acts as a substrate for HBV polymerase. The 
information of further viral DNA is blocked by incorporation of triphosphate into the 
viral chain and by subsequent chain termination. At the same time lamivudine not enter 
to normal cellular DNA. They inhibit the HIV reverse transcriptase enzyme competitively 
and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the 
incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester 
linkage essential for DNA chain elongation, and therefore, the viral DNA growth is 
terminated. 
 
Mechanism of action: 
Lamivudine is analogue of cytidine. It inhibits both type (1 and 2) of HIV reverse 
transcriptase and also reverse transcriptase of hepatitis B. It is phosphorylated to active 
metabolites that complete for incorporation in to viral DNA. It inhibits the HIV reverse 
transcriptase enzyme competitively and chain terminator of DNA synthesis. The lack of a 
3-OH group in the incorporation nucleoside analogue prevents the formation of the 5 to 3 
phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA 
growth is terminated. Several mutagenicity tests show that lamivudine should not show 
mutagenic activity in therapeutic doses. And some research shows lamivudine can cross 
the blood brain barrier. 
 
Pharmacodynamics  
 
Lamivudine is an antiviral agent which is highly active against hepatitis B virus in 
virus-transfected human hepatoma cell lines and in experimentally infected animals. 
Lamivudine is metabolised by both hepatitis B virus-transfected and non-transfected 
hepatoma cells to the triphosphate (TP) derivative which is the active form of the parent 
compound. The intracellular half life of the triphosphate in hepatoma cells is 17 – 19 
hours in vitro. Lamivudine acts as a substrate for the HBV viral polymerase. It is 
considered that the formation of further viral DNA is blocked by incorporation of 
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lamivudine into the chain and subsequent chain termination. Lamivudine does not 
interfere with cellular deoxynucleotide metabolism. It is also a weak inhibitor of 
mammalian DNA polymerases alpha and beta. Furthermore, lamivudine has little effect 
on mammalian cell DNA content.  
Pharmacokinetics 
Absorption:  
Lamivudine is well absorbed from the gut, and the bioavailability of oral 
lamivudine in adults is normally between 80 and 85%. Following oral administration the 
mean time (tmax) to maximal serum concentrations (Cmax) is about an hour. At 
therapeutic dose levels 100mg once daily, Cmax is in the order of 1-1.5 µg/mL and 
trough levels were 0.015 – 0.020 µg/mL.  
Distribution:  
From intravenous studies, the mean volume of distribution is 1.3 L/kg. 
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and 
displays low plasma protein binding to albumin. Limited data show relatively low 
penetration of lamivudine into the central nervous system. The mean ratio CSF/serum 
lamivudine concentration 2 to 4 hours after oral administration was approximately 0.12.  
Metabolism:  
Lamivudine is predominately cleared by renal excretion of unchanged drug. The 
likelihood of metabolic drug interactions with lamivudine is low due to limited 
metabolism and plasma protein binding and almost complete renal clearance. An 
interaction with trimethoprim, a constituent of co-trimoxazole (trimethoprim with 
sulphamethoxazole) causes a 40% increase in lamivudine exposure at therapeutic doses.  
Elimination:  
The mean systemic clearance of lamivudine is approximately 0.3 L/h/kg. The 
observed half-life of elimination is 5 to 7 hours. The majority of lamivudine is excreted 
unchanged in the urine via glomerular filtration and active secretion (organic cationic 
transport system). Renal clearance is about 70% of lamivudine elimination 
Side effect 
Abdominal pain, vomiting, diarrhea, insomnia, cough, nasal a symptoms, muscles 
pain, head ach, fever, rash, alopecia, malaise, increased creatinine, phospholinase. 
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pKa 
Lamivudine is a weak base with a pKa of 4.3 ( protonation of the NH2 group) 
 
Dosage 
Oral chronic Hepatitis B 
 Chronic Hepatitis B: Adult- 100 mg once daily. Child - >2yrs: 3 mg/kg once 
daily. Max 100 mg/day. HIV infection: Concomitant HIV & hepatitis B infection: Adult - 
150 mg bid or 300 m once daily in combination with other antiretrovirals. Child- 
3months - 12 yrs: 4 mg/kg bid. Max: 300 mg/day.  
 
Concomitant HIV& hepatitis B infection: 
 Adult - 150 mg or 300 mg once daily combination with other antiretroviral drugs. 
 Child-3 months-12years: 4 mg/kg bid. Max: 300 mg/day. 
Storage 
Keep container tightly closed. Keep container in a well-ventilated area and 
protected from light it may exhibit polymorphism 
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5.3 POLYMER PROFILE 
EUDRAGIT RS 100 
Molecular weight 
 150.000 
Chemical Structure 
 
 
 
R1=CH3 
R2=C2H5 
R3=CH3 
R4=CH2CH2n(CH3)3+C1 
  
 Eudragit RS 100 is the copolymer of ethyl acrylate, methyl methacrylate and a 
low content of methacrylic acid ester with quaternary ammionium group. The group 
are present as salts and make the polymers permiable. 
 
Chemical name 
 Poly (ethyl acrylate-co-methyl methacrylate-co-trimethyl ammino ethyl 
methacrylate chloride) 1:2:0:1. 
 
INCI name 
 Acrylates/ ammonium methacrylate co polymer. 
 
Physical properties 
 Colourless, clear to cloud granules with a faint amine-like odour. 
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Solubility 
 Soluble in methanol, ethanol, isopropyl alcohol, acetone, ethyl acetate, 
methylenechloride. Insoluble in petroleum ether and 1 N sodium hydroxide, water.  
 
Functional Category 
Tablet diluents 
 
Application in pharmaceutical formulation and technology: 
 
Used to form water insoluble film or film coats for sustained release product, 
these are also permeable to solvents. 
 
Plasticizers 
 This includes dibutyl phthalate,poly ethylene glycols and tri ethyl citrate. 
 
Storage 
 Stored at controlled room temperature (USP General noticed). Protect against 
moisture stored at 8degree. Avoid contacting with atmospheric moisture. Store the 
materials with a desiccant in original containers to maintain product quality. Keep the 
container closed until it is ready for use. 
 
5.4 EUDRAGIT RL 100 
Molecular weight  
 150.000 
Chemical Structure  
 
R1=H 
R2=CH3 
R3=CH3 
R4=CH2CH2.N(CH3)3C1 
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 Eudragit RL100 is the copolymer of ethyl acrylate, methyl methacrylate and a 
low content of methacrylic acid ester with quaternary ammionium group.The group 
are present as salts and make the polymers permiable. 
 
Chemical name 
 Poly (ethyl acrylate-co-methyl methacrylate-co-trimethyl ammino ethyl 
methacrylate chloride)1:2:0:2. 
 
INCI name 
 Acrylates/ ammonium methacrylate co polymer. 
 
Physical properties 
Colourless, clear to cloud granules with a faint amine-like odour. 
 
Solubility  
 Soluble in methanol, ethanol and isopropyl alcohol, acetone, ethyl acetate and 
methylene chloride. Insoluble in petroleum ether and 1 N sodium hydroxide, water. 
 
Functional Category 
Film former, Tablet diluents. 
 
Application in pharmaceutical formulation and technology: 
 Used to form water insoluble film or film coats for sustained release product, 
these are also permeable to solvents. 
 
Plasticizers  
 This includes dibutyl phthalate,poly ethylene glycols and tri ethyl citrate. 
 
Storage 
 Stored at controlled room temperature (USP General Notice) protect against 
moisture. Avoid contacting with atmospheric moisture. Store the materials with a 
desiccant in original containers to maintain product quality. Keep the container closed 
until it is ready for use. 
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5.5 POLYVINYL ALCOHOL72 
 
Synonym 
Airvol, Elvanol,Polyviol, Poval, PVA, Vinyl alcohol polymer 
Chemical name 
Ethanol, Homopolymer 
 
Empirical formula 
 (C2H4O) n  
 
Molecular weight 
30, 000 to 200,000 
 
Chemical Structure  
 
CH2
H
C
OH n
 
 
Description 
Colour   : white to cream-colored granular powder. 
Odour   : odourless 
Melting point  : 228° C for fully hydrolyzed grades, 80-190°C for 
                                              partially hydrolyzed grades. 
Refractive index  : 1.49-1.53 
 
Solubility 
Soluble in hot or cold water, slightly soluble in some polyhydroxy                         
compounds, certain amines and amides. Insoluble in aliphatic, aromatic and 
chlorinated hydrocarbons, esters, ketones, oils. 
 
Functional category 
Coating agent, Nonionic Surfactant, Viscosity builder 
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Applications 
It is used primarily in topical pharmaceutical formulations, particularly in 
ophthalmic products as a viscosity increasing agent, as a stabilizing agent for 
emulsions. 
Pharmacopeia Specifications: 
pH (4% aqueous solution )   = 5 to 8 
Loss on drying            = 5% 
Residue on ignition   = 2% 
Water – insoluble substances  = 0.1% 
Degree on hydrolysis    = 85 to 89% 
 
Stability and Storage Conditions: 
            PVA undergoes slow degradation at 190˚C and rapid degradation at 200˚C, 
stable on exposure to light. Aqueous solutions are stable and should be stored in 
corrosion resistant containers. For extended storage preservative should be added. The 
bulk should be stored in a well closed container, in a cool, dry place. 
 
 
EXPERIMENTAL INVESTIGATION 
 
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai Page 62 
 
 6.  EXPERIMENTAL INVESTIGATIONS 
 
6.1. CONSTRUCTION OF STANDARD CURVE FOR LAMIVUDINE69,75 
A. By UV Spectroscopy Method 
              Lamivudine is estimated spectrophotometrically at 270 nm and it obeys Beer- 
Lambert’s Law in the range of 2 – 20 µg/ml.     
                                                                
Determination of Absorbance maximum (λmax) 
 Lamivudine was dissolved in phosphate buffer saline pH 7.4. Solution with 20 
µg/ml concentration was prepared by suitable dilution. The solution was scanned in 
UV spectrophotometer at 200 to 400 nm using phosphate buffer saline pH 7.4 as 
blank. Absorbance maximum was determined as 270 nm. The drug was later 
quantified by measuring the absorbance at 270 nm in phosphate buffer saline pH7.4.   
              
Preparation of pH 7.4 Phosphate Buffer Saline56  
 Disodium hydrogen phosphate 2.38 gm, potassium di-hydrogen phosphate 
0.19 gm, sodium chloride 8 gm accurately weighed and it is transformed in to 1000 
ml volumetric flask and volume is made up with distilled water. The pH was adjusted 
if necessary. 
Preparation of Stock solution                                                                                                        
 
 Stock solution was prepared by dissolving 100 mg of Lamivudine drug in 100 
ml of solvent medium, so as to get a solution of 1000 µg/ml concentration (Primary 
stock solution) From primary stock solution 2 ml was taken in 100 ml standard flask 
and it diluted to100 ml with solvent medium PBS pH 7.4 (secondary stock solution) 
to get the concentration of 2-20 mcg/ml. 
 
Preparation of Standard solution 
    From the secondary stock solution aliquots ranging from 1to10 ml with PBS to 
get the final concentration ranges from 2 to 20 µg per ml.  Absorbance of the solution 
was measured at 270 nm UV spectrophotometrically against drug free PBS pH 7.4 
media as blank.   
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Table: 8: CALIBRATION CURVE OF LAMIVUDINE AT 270 nm 
 
S.NO Concentration 
(µg/ml) 
Absorbance at 
270nm 
1 2 0.066 
2 4 0.152 
3 6 0.226 
4 8 0.284 
5 10 0.374 
6 12 0.441 
7 14 0.517 
8 16 0.591 
9 18 0.669 
10 20 0.746 
 
 
FIGURE: 7: STANDARD CURVE FOR LAMIVUDINE 
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PREFORMULATION STUDY 
6.2 DRUG AND POLYMER COMPATABLITY STUDY BY FTIR18,24,35 
One of the requirements for the selection of suitable excipient (or) carrier for 
pharmaceutical formulations is its compatibility. Therefore in the present work, a 
study was carried out using Fourier Transformed Infrared (FT-IR) spectrophotometer 
(using Perkin Elmer) to confirm the absence of any possible chemical interactions 
between the Lamivudine and Eudragit RS 100 & Eudragit RL 100. 
Infrared spectroscopy by potassium bromide pellet method was carried out on 
pure substances (Lamivudine and Eudragit RS 100 & Eudragit RL 100) separately 
and their physical mixtures. They are compressed under 15 tonnes pressure in a 
hydraulic press to form a transparent pellet. The pellet was scanned from 4000 to 400 
cm-1 in a spectrophotometer. 
           The spectrum of physical mixtures was compared with the original spectra to 
determine any possible molecular interactions between the drug and polymer. Fourier 
Transformer Infrared Spectroscopy (FTIR) analysis measures the selective absorption 
of light by the vibration modes of specific chemical bonds in the sample. The 
observation of vibration spectrum of encapsulated drug evaluates the kind of 
interaction occurring between the drug and polymer.  
         In the present work, Lamivudine pure drug, pure Eudragit RS 100 & Eudragit 
RL 100 was submitted to FTIR and spectra are obtained. They are compressed under 
10 tonnes pressure in a hydraulic press to form a transparent pellet. The pellet was 
scanned from 4000 to 400 cm-1 in a spectrophotometer. 
 
IR SPECTRA DATA FOR PURE DRUG LAMIVUDINE 
Table: 9: 
 
 
Frequency cm-1 Groups Assigned 
1637.71 
3328.32 
1286.72 
3214.01 
2924.56 
C=O - Stretching 
NH   - Stretching 
C-O - Stretching 
O-H - Stretching 
C-H - Stretching 
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IR SPECTRA DATA FOR EUDRAGIT RS 100 
Table: 10 
 
Frequency cm-1 Groups Assigned 
2928 
1740 
1466 
1021 
CH -Stretching 
C =O-Stretching 
CH -Stretching 
CO-Stretching 
 
 
IR SPECTRA DATA FOR EUDRAGIT RL 100 
Table: 11 
 
Frequency cm-1 Groups Assigned 
2932 
1740 
1466 
1021 
CH -Stretching 
C =O-Stretching 
CH -Stretching 
CO-Stretching 
 
IR SPECTRA DATA FOR PHYSICAL MIXTURE 
Table: 12 
 
Frequency cm-1 Groups Assigned 
1637.71 
3328.32 
1286.72 
3214.01 
2924.56 
C=O - Stretching 
NH   - Stretching 
C-O - Stretching 
O-H - Stretching 
C-H - Stretching 
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6.3. METHOD OF PREPARATION OF LAMIVUDINE NANOPARTICLES: 
  Emulsion Solvent Evaporation Method21,37,378,49 
 All batches of nanoparticles were prepared by Emulsion Solvent Evaporation 
method. The required quantity of polymer was dissolved in 4 ml methanol and 2 ml 
chloroform in (2:1) ratio as organic phase. The organic phase was then mixed with an 
aqueous phase containing drug and 0.2% polyvinyl alcohol (4 ml). The polymer 
concentration differs in various batches formulation as given in table; 15 
 
Table 15: Various Composition of Nanoparticles Formulation 
 
S.NO 
 
Formulation 
Code 
Drug 
(Lamivudine) 
in mg 
Polymer 
Eudragit 
RS 100 
Polymer 
Eudragit 
RL100 
 
Drug: 
Polymer 
Ratio 
1 F1 10 30 - 1:3 
 
2 F2 10 20 - 1:2 
 
3 F3 10 10 - 1:1 
 
4 F4 10 - 30 1:3 
 
5 F5 10 - 20 1:2 
 
6 F6 10 - 10 1:1 
 
7 
 
F7 10 15 15 1:1 
8 
 
F8 10 20 10 2:1 
9 
 
F9 10 25 5 2.5:0.5 
10 F10 10 27.5 2.5 2.75:0.25 
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 This mixture was homogenized by vortex mixture for 1 min and then 
sonicated using a probe sonicator set at 55W of energy output for 1min to form an oil-
in-water emulsion. The emulsion thus formed was further evaporated by flash rotatory 
evaporator for 20 min. The nanoparticle was collected by ultra-centrifugation (15,000 
rpm). 
 
Fig: 8: Schematic representation of Emulsion Solvent Evaporation method 
 
 
 
The prepared nanoparticles are washed with water. The washed liquid was 
eliminated by centrifugation and purified nanoparticle was collected. 
 
6.4. EVALUATION OF NANOPARTICLES42 
6.4.1 DRUG ENTRAPMENT STUDY 
The entrapment efficiency study was determined by free drug content in the 
supernatant which is obtained after centrifuging the solid lipid suspension at 
(15,000rpm for 20 min at zero degree using ultra  centrifuge) The absorbance was 
measured at 270 nm by UV spectrophotometrically. 
 
 
 
Distilled, water
 
 
 
Drug, Stabilizer 
  
Polymer, Solvent,
 
 
 
Organic phase  
  
 
Sonication  
Homogenization  
O/W Emulsion   
  
Solvent evaporation  
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6.4.2 INVITRO DRUG RELEASE STUDIES29,35 
 By UV Spectrophotometric Method45 
The in vitro drug release study was carried out by using the diffusion 
membrane technique. The nanoparticles preparation was placed in a dialysis 
membrane and it is dropped in to a beaker containing 200 ml of diffusion medium 
(phosphate buffer saline pH 7.4) the medium was maintained at 370 C under magnetic 
stirring at constant speed. At fixed time interval 1ml of sample was taken from the 
diffusion medium for every 1 hour and it was replaced by 1ml fresh medium. This 
process was carried out for 24 hours. The sample was measured UV 
spectrophotometrically at 270 nm. The percentage of drug released at various time 
intervals was calculated from calibration graph. 
 
6.4.3 MORPOLOGY OF NANOPARTICLES BY SIMPLE MICROSCOPY: 
The optimized formulation was morphologically characterized by microscopy. 
The small amount sample was placed in a glass slide and investigated in microscopy.  
 
6.4.4 SCANNING ELECTRON MICROSCOPY39 
 The optimized formulation was morphologically characterized by scanning 
electron microscopy (SEM). The sample for SEM analysis was mounted in the 
specimen using an adhesive small sample was mounted directly in scotsch double 
adhesive tape. The sample was analyzed in hitachi scanning electron microscope 
operated at 15 kv and photograph was taken. 
 
6.4.5 SURFACE CHARGE (ZETA POTENTIAL) DETERMINATION43 
 Zeta potential is an important parameter to evaluate and establish an optimum 
condition for stability of colloidal or dispersed systems. The prepared nanoparticle 
suspensions were characterized with respect to zeta potential by using zeta potential 
analyser (Malvern Zeta seizer). Zeta potential is electrical charges on particles surface 
it create electrical barrier it is very important for drug stability. The effect of Eudragit 
RS100 & Eudragit RL100 (polymer) on the surface characteristics of the nanoparticle 
was studied. 
 
6.4.6 pH AND PHYSICAL APPEARANCE: 
 The pH of the formulation was measured using pH meter. It plays a vital role 
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in process of stability and formulation activity. The physical appearance of the 
formulation such as colour and suspended foreign particulate matter were to be 
examined. 
 
STERILIZATION OF NANOPARTICLES 
The prepared nanoparticles were administered as injection, so it needs to 
sterilize. The sterilization process was carried out by membrane filter placed with 0.4 
micron membrane. The prepared nanoparticle suspension was allowed to flow 
through the membrane filter. This whole process can carry out in aseptic condition 
maintained by laminar air Flow Bench. The sterilized nanoparticle suspension was 
stored in suitable container. 
 
6.4.7 STERILITY TESTING OF NANOPARTICLES73: 
 
STERILITY TEST PROCEDURE: 
The sterility test is a important for nanoparticle because it’s a parental 
formulation. The sterility test for nanoparticles is done by various medium as per IP. 
  
PREPARATION OF SOYABEAN CASEIN MEDIUM (SCDM); 
            25 gms of dehydrated media was weighed and mix with small amount of 
freshly prepared hot water and made up to 1000 ml with hot water in a 1000 ml 
beaker. The medium was cooled to room temperature and pH adjusted to 7.3 ± 0.2. 
The medium was dispensed in suitable container and sterilized at 121oC for 15 min.  
 
PREPARATION OF FLUID THIOGLYCOLLATE MEDIUM (FTM): 
  26 gm of dehydrated media was weighed and mix with small amount of 
freshly prepared hot water and made up to 1000 ml with hot water in a 1000 ml 
beaker. The medium was adjusted to pH7.1 ± 0.2. The sterilized media should not 
have more than upper one third of the medium in pink color.  
Preparation of rinsing fluid (Fluid A):  
 1 gm of peptic digest of animal tissue was weighed and taken and mixed up 
with small amount of freshly prepared  hot water and made up to one 1000 ml in a  
beaker. The solution was filtered and pH adjusted to pH 7.1 ± 0.2. The solution was 
then dispensed in suitable container and autoclaved at 1210 C 15 min for sterilization.  
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Procedure:  
The vials containing Lamivudine loaded nanoparticles were broken open 
under aseptic condition provided by laminar air flow works. All precautions and 
preventive measures were taken to avoid contamination by the process or by the 
analyst. The drug solution was then passed through sterile membrane lodged on a 
membrane holder assembly. After passing through the solution the membrane was 
rinsed with thrice with 100 ml of sterile peptone (Fluid A). The membrane was then 
cut into two halves using sterile scissors. One half of the filter paper was introduced 
into the container with SCDM and the other half in to the container with FTM.  
 
           This prepared medium is placed in different temperature. Soybean casein 
digest medium (SCDM) is incubated at 22.5oC ± 2.50C and Fluid thioglycollate 
medium (FTM) is incubated at 32.50c ± 2.50C. The containers were observed for 
turbidity or appearance growth of microorganism for 14 days. Positive control and 
negative control test were done to validate the sterility testing procedure.  
 
Negative control: 
            Negative control confirms the sterility of the sterilized media. It was the 
uninnoculated sterile media and observed for 14 days. Negative control was 
maintained for both (FTM) and (SCDM) Medias and incubated in the appropriate 
temperature.  
Positive control:  
            Positive control confirms the suitability of the media for the growth of 
microorganism. The positive control for SCDM and FTM was inoculated with 
Bacillus subtilis suspension with less than 100 CFUs and incubated recommended 
temperature respectively for 14 days. The growth of micro organism witnessed by the 
turbidity of the medium confirms the presence of nourishments favoring 
Microorganism. 
 
6.4.8 STABILITY STUDIES OF NANOPARTICLES59,74 
      The Stability studies of nanoparticles involves observing the formulation at 
45°C/70% RH which constitutes Accelerated condition and 4°C on refrigerator and 
room temperature.  The formulations were kept in both the temperature for 3 months 
and sufficient amount of samples were taken at periodic intervals for performing the 
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following tests.   
  
  a. Physical appearance   
  b. pH of the solution 
  c. In vitro drug release (Dissolution)  
                        d. Percentage of drug entrapment 
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7. RESULTS AND DISCUSSION 
7.1. DEVELOPMENT OF LAMIVUDINE NANOPARTICLES21 
 In this study, Lamivudine loaded nanoparticles were prepared by Emulsion 
solvent evaporation method using Eudragit RS 100 & Eudragit RL100, methanol and 
chloroform solvent are used in the ratio of (2:1). The organic phase was then mixed 
with an aqueous phase containing drug and 0.2% polyvinyl alcohol. This mixture was 
homogenized by vortex for 1 min and then sonicated using a probe sonicator to form 
an oil-in-water emulsion. The emulsion thus formed was further evaporated by flash 
rotatory evaporator for 20 min. 
 
Formulations with different ratios of polymer were prepared. Several 
physicochemical characteristics of nanoparticles such as morphology, particle size 
determination, drug release profile were investigated and stability of optimized 
formulation at various temperatures was evaluated.  
 
7.2 DRUG & POLYMER COMPATIBILITY STUDIES BY FTIR25, 48 
Pressed Pellet Technique was used to handle the sample in FTIR spectrometer. 
In this technique a pinch of sample was mixed with potassium bromide and the 
mixture was pressed with special discs under high pressure into a transparent pellet 
and then inserted in to special holder of IR spectrometer. 
  
IR spectrums for pure drug alone and physical mixture of drug and polymers 
are taken. The spectrum of physical mixture was compared with spectrum of pure 
drug. Bands seen in pure drug also recognized in physical mixture. Hence there was 
no significant interaction between drug and excipients.    
 
7.3 ENTRAPMENT EFFICIENCY OF NANOPARTICLE44 
 
The Entrapment efficiency of Lamivudine loaded nanoparticles was prepared 
by Emulsion solvent evaporation method. The formulation F1 (Lamivudine 10 mg 
with 30mg of Eudragit RS 100) which shows less entrapment value of 61% was 
represented in table no.16. This is due to repulsive force between drug and the 
polymer.  
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Table: 16: Entrapment efficiency formulations with Drug and polymer: 
 
S.NO Formulation 
Code 
Drug  
(mg) 
Eudragit 
RS 100 
(mg) 
Eudragit 
RL 100 
(mg) 
Entrapment 
Efficiency 
(%) 
1 F1 10 30 - 61±0.12 
2 F2 10 20 - 68±0.09 
3 F3 10 10 - 72± 0.17 
4 F4 10 - 30 49±0.14 
5 F5 10 - 20 56±0.11 
6 F6 10 - 10 60±0.08 
7 F7 10 15 15 73±0.12 
8 F8 10 20 10 83±0.17 
9 F9 10 25 5 94±0.05 
10 F10 10 27.5 2.5 85±0.08 
 
In formulation (F2) polymer concentration was decreased (Lamivudine 10 mg 
Eudragit 20 mg) the entrapment efficiency was increased to 68%. Further decrease in 
polymer concentration in formulation F3 (Lamivudine 10 mg Eudragit 10 mg) 
entrapment efficiency was 72%. Formulation F4, F5, F6, carried out by same process 
as like first three formulation but changes in polymer concentration 30 mg, 20 mg, 10 
mg of (Eudragit RL 100) is taken. The entrapment efficiency was 49 ± 0.03 for F4, 56 
% for F5, 60% for F6. Based on above result. 
 Formulation F7 was carried out by combination of both polymers intially with 
same concentration (Lamivudine 10 mg Eudragit RS100 15 mg RL 100 15 mg) were 
taken. Entrapment efficiency was increased in great number F7 73% and also in F8 
83%. In order to study the polymer concentration the formulation F9 was carried out 
in different concentration (Lamivudine 10 mg with 25 mg of  Eudragit RS 100 and 5 
mg of Eudragit RL 100) it give high percentage of entrapment efficiency 94%, which 
indicate the steady increasea in entrapment efficiency. 
 Further study was carried out in F10 changes in polymer concentration 
(Lamivudine 10 mg with 27.5 mg of Eudragit 100 and 2.5 mg of Eudragit RL 100) 
entrapment efficiency is 85% was not as like F9. From the above result formulation 
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F9 shows highest percentage  of entrapment efficency of 94%. So this formulation 
was selected for further studies . 
The drug entrapment efficiency  is based on chemicals structure of drug and 
polymer used. Eudragit RS100 contains more  number of non polar group but 
Eudragit RL 100 contain more number of polar group, at the same time Lamivudine 
have more number of non polar. So Eudragit RS 100 has less repulsive force with 
Lamivudine drug molecules. So the entrapment efficiency is high inFormulation F9. 
 
7.4 INVITRO DRUG RELEASE PROFILE OF NANOPARTICLES30,40,41 
 The in vitro drug release of lamivudine nanoparticle can carried out by 
membrane diffusion method and in vitro drug release study was carried out for 
24 hours. 
 The in vitro drug release of lamivudine loaded nanoparticles with various 
polymers (Eudragit RS 100 & Eudragit RL 100). 
 The in vitro drug release of formulation F1 (Lamivudine 10 mg with 30 mg of 
Eudragit RS 100). The percentage of in vitro drug release was 59.57% in 24 
hours.  
 The formulation F2 was carried out by decreasing the polymer concentration 
(Lamivudine 10 mg with 20 mg of Eudragit RS 100). The percentage of in 
vitro drug release was found to be 66.65%  
 The formulation F3 was carried out by further decrease in polymer 
concentration (Lamivudine 10 mg with10mg of Eudragit RS 100). The 
percentage of drug release was 70.68 % shown in the table 13.  
 The formulation F4 was prepared by replacing the polymer with Eudragit RL 
100. (Lamivudine 10 mg with 30 mg of Eudragit RL 100) The in vitro drug 
release was found to be 52.50% in 24 hours. The formulation F5 and F6 was 
done by further decrease in polymer concentration. The in vitro drug release 
was 60.58% and 69.61 % respectively. 
 The formulation F7 was carried out by combination of two polymers in same 
concentration (Lamivudine 10 mg Eudragit RS 100 15 mg & Eudragit RL 100 
15 mg) due to the combination of polymer it intent to modified the surface 
characteristics. So the percentage of drug release was found to be 71.65% in 
24 hours as given table: 23 
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 The formulation F8 was done by increase the polymer concentration of 
Eudragit RS100 and decreases the polymer concentration of Eudragit RL100. 
(Lamivudine 10 mg with 20 mg of Eudragit RS 100& 10 mg of Eudragit RL 
100) as the result of these changes, in vitro drug release was increased 81.97% 
when comparing with other formulation. 
 The  formulation F9 was carried out by same process as like F7 & F8  but 
changes in the polymer concentration (Lamivudine 10 mg  with 25 mg  of 
Eudragit RS 100 & 5 mg Eudragit RL 100  ) in vitro drug release was found to 
be 92.89% it will show the highest percentage  of drug release when 
comparing with other formulation 
 Further study was carried out by increasing the polymer concentration of 
Eudragit RS 100 (Lamivudine 10 mg with 27.5 mg of Eudragit RS 100 & 2.5 
mg Eudragit RL 100) percentage of drug release was found to be 83.78%, 
which shows less in vitro drug release when compared with F9. 
 From the above formulation (F1 to F10) it confirms that the percentage of drug 
release was satisfactory in formulation F9 and it shows higher percentage of 
drug release of 92.89 %. So it was decided to be the best formulation. So it 
optimized for further study. 
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Table: 17: In vitro drug release for F1 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.4 0.4 4.0 
2 0.8 0.804 8.04 
3 1.0 1.008 10.08 
4 1.2 1.210 12.10 
5 1.6 1.612 16.12 
6 1.9 1.916 19.16 
7 2.2 2.219 22.19 
8 2.3 2.322 23.22 
9 2.5 2.523 25.23 
10 2.7 2.725 27.25 
11 3.0 3.027 30.27 
12 3.2 3.230 32.30 
13 3.3 3.332 33.32 
14 3.5 3.533 35.33 
15 3.9             3.935 39.35 
16 4.0 4.039 40.39 
17 4.3 4.340 43.40 
18 4.4 4.443 44.43 
19 4.6 4.644 46.44 
20 5.1 5.146 51.46 
21 5.5 5.551 55.51 
22 5.6 5.655 56.55 
23 5.7 5.756 57.56 
24 5.9 5.957 59.57 
 
Figure No: 9: IN VITRO DRUG RELEASE FOR FORMULATION F1 
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Table: 18: In vitro drug release for F2 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.6 0.6 6.0 
2 0.8 0.806 8.06 
3 1.2 1.208 12.08 
4 1.3 1.312 13.12 
5 1.5 1.513 15.13 
6 1.9 1.915 19.15 
7 2.0 2.019 20.19 
8 2.3 2.320 23.20 
9 2.6 2.623 26.23 
10 2.8 2.826 28.26 
11 3.2 3.228 32.28 
12 3.4 3.432 34.32 
13 4.0 4.034 40.34 
14 4.2 4.240 42.40 
15 4.6 4.642 46.42 
16 4.9 4.946 49.46 
17 5.0 5.049 50.49 
18 5.2 5.250 52.50 
19 5.4 5.452 54.52 
20 5.5 5.554 55.54 
21 6.0 6.055 60.55 
22 6.3 6.360 63.60 
23 6.5 6.563 65.63 
24 6.6 6.665 66.65 
 
Figure No: 9: IN VITRO DRUG RELEASE FOR FORMULATION F2 
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Table: 19: In vitro drug release for F3
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.7 0.7 7.0 
2 0.9 0.907 9.07 
3 1.3 1.309 13.09 
4 1.5 1.513 15.13 
5 1.9 1.915 19.15 
6 2.1 2.119 21.19 
7 2.6 2.621 26.21 
8 2.9 2.926 29.26 
9 3.1 3.129 31.29 
10 3.3 3.331 33.31 
11 3.6 3.633 36.33 
12 3.9 3.936 39.36 
13 4.0 4.039 40.39 
14 4.4 4.440 44.40 
15 4.6 4.644 46.44 
16 4..8 4.846 48.46 
17 5.1 5.148 51.48 
18 5.2 5.251 52.51 
19 5.6 5.652 56.52 
20 5.9 5.956 59.56 
21 6.2 6.259 62.59 
22 6.4 6.462 64.62 
23 6.8 6.864 68.64 
24 7.0 7.068 70.68 
 
Figure No: 10: IN VITRO DRUG RELEASE FOR FORMULATION F3 
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Table: 20: In vitro drug release for F4 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.4 0.4 4 
2 0.6 0.604 6.04 
3 0.9 0.906 9.06 
4 1.4 1.409 14.09 
5 1.5 1.514 15.14 
6 1.7 1.715 17.15 
7 1.9 1.917 19.17 
8 2.2 2.219 22.19 
9 2.3 2.322 23.22 
10 2.5 2.523 25.23 
11 2.7 2.725 27.25 
12 2.8 2.827 28.27 
13 3.0 3.028 3.28 
14 3.1 3.130 31.30 
15 3.3             3.331 33.31 
16 3.4 3.433 34.33 
17 3.6 3.634 36.64 
18 3.7 3.736 37.36 
19 4.1 4.137 41.37 
20 4.4 4.441 44.41 
21 4.6 4.644 46.44 
22 4.7 4.746 47.46 
23 5.0 5.047 50.47 
24 5.2 5.250 52.50 
 
Figure No: 11: IN VITRO DRUG RELEASE FOR FORMULATION F4 
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Table: 21: In vitro drug release for F5
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.4 0.4 4 
2 0.8 0.804 8.04 
3 0.9 0.908 9.08 
4 1.2 1.209 12.09 
5 1.4 1.412 14.12 
6 1.7 1.714 17.14 
7 1.8 1.817 18.17 
8 1.9 1.918 19.18 
9 2.1 2.119 21.19 
10 2.4 2.421 24.21 
11 2.6 2.624 26.24 
12 2.7 2.726 27.26 
13 3.0 3.027 30.27 
14 3.5 3.530 35.30 
15 3.6 3.635 36.35 
16 3.8 3.836 38.36 
17 4.2 4.238 42.38 
18 4.4 4.442 44.42 
19 4.5 4.544 45.44 
20 5.0 5.045 50.45 
21 5.3 5.350 53.50 
22 5.4 5.453             54.53 
23 5.8             5.854 58.54 
24 6.0 6.058 60.58 
 
Figure No: 12: IN VITRO DRUG RELEASE FOR FORMULATION F5 
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Table: 21: In vitro drug release for F6
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.4 0.40 0.40 
2 0.5 0.504 05.04 
3 0.8 0.805 08.05 
4 1.1 1.108 11.08 
5 1.2 1.211 12.11 
6 1.5 1.512 15.12 
7 1.9 1.915 19.15 
8 2.4 2.419 24.19 
9 2.5 2.524 25.24 
10 3.0 3.025 30.25 
11 3.1 3.104 31.30 
12 3.3 3.331 33.31 
13 3.9 3.933 39.33 
14 4.0 4.039 40.39 
15 4.2 4.240 42.40 
16 4.6 4.642 46.42 
17 4.7 4.746 47.46 
18 5.0 5.047 50.47 
19 5.1 5.150 51.50 
20 5.3 5.351 53.51 
21 5.7 5.753 57.53 
22 5.8 5.857 58.57 
23 6.1 6.158 61.58 
24 6.7 6.761 67.61 
 
Figure No: 13: IN VITRO DRUG RELEASE FOR FORMULATION F6 
 
Slope = 2.759       r2 = 0.993 
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Table: 23: In vitro drug release for F7
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.2 0.2 2.0 
2 0.5 0.502 5.02 
3 0.7 0.705 7.05 
4 0.8 0.807 8.07 
5 1.3 1.308 13.08 
6 1.5 1.513 15.13 
7 1.9 1.915 19.15 
8 2.5 2.519 25.19 
9 2.6 2.625 26.25 
10 3.0 3.026 30.26 
11 3.1 3.130 31.30 
12 3.3 3.331 33.31 
13 3.6 3.633 36.33 
14 3.8 3.836 38.36 
15 4.2 4.238 42.38 
16 4.3 4.342 43.42 
17 4.5 4.543 45.43 
18 4.8 4.845 48.45 
19 5.1 5.148 51.48 
20 5.5 5.551 55.51 
21 6.0 6.055 60.55 
22 6.3 6.360 63.60 
23 6.5 6.563 65.63 
24 7.1 7.165 71.65 
 
Figure No: 14: IN VITRO DRUG RELEASE FOR FORMULATION F7 
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Table: 24: In vitro drug release for F8
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.5 0.5 0.5 
2 0.7 0.705 07.05 
3 1.0 1.007 10.07 
4 1.5 1.510 15.10 
5 1.6 1.615 16.15 
6 1.8 1.816 18.16 
7 2.5 2.518 25.18 
8 2.8 2.825 28.25 
9 3.3 3.328 33.28 
10 3.4 3.433 34.33 
11 3.9 3.934 39.34 
12 4.1 4.139 41.39 
13 4.5 4.541 45.41 
14 4.7 4.745 47.45 
15 5.5 5.547 55.47 
16 5.7 5.755 57.55 
17 6.1 6.157 61.57 
18 6.6 6.661 66.61 
19 6.9 6.966 69.66 
20 7.2 7.269 72.69 
21 7.4 7.472 74.72 
22 7.6 7.674 76.74 
23 7.9 7.976 79.76 
24 8.1 8.197 81.97 
 
Figure No: 15: IN VITRO DRUG RELEASE FOR FORMULATION F8 
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Table: 25: In vitro drug release for F9
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.8 0.8 8.0 
2 1.5 1.508 15.08 
3 1.9 1.918 19.18 
4 2.3 2.319 23.19 
5 2.6 2.623 26.23 
6 3.2 3.226 32.26 
7 3.8 3.832 38.32 
8 4.0 4.038 40.38 
9 4.4 4.440 44.40 
10 4.7 4.744 47.44 
11 5.2 5.247 52.47 
12 5.3 5.352 53.52 
13 5.8 5.853 58.53 
14 6.0 6.058 60.58 
15 6.7 6.760 67.60 
16 6.9 6.967 69.67 
17 7.2 7.269 72.69 
18 7.3 7.372  73.72 
19 7.9 7.973 79.73 
20 8.2 8.279 82.79 
21 8.4 8.482 84.82 
22 8.5 8.584 85.84 
23 8.9 8.985 89.85 
24 9.2 9.289 92.89 
 
Figure No: 16: IN VITRO DRUG RELEASE FOR FORMULATION F9 
 
Slope = 3.704       r2 = 0.988 
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Table: 26: In vitro drug release for F10
 
 
Time 
(Hrs) 
Amount of drug 
release (mg) 
Cumulative amount 
of drug release 
Cumulative % 
drug release 
1 0.8 0.8 8.0 
2 1.5 1.508 15.08 
3 1.9 1.918 19.18 
4 2.3 2.319 23.19 
5 2.6 2.623 26.23 
6 3.2 3.226 32.26 
7 3.8 3.832 38.32 
8 4.0 4.038 40.38 
9 4.4 4.440 44.40 
10 4.7 4.744 47.44 
11 5.2 5.247 52.47 
12 5.3 5.352 53.52 
13 5.8 5.853 58.53 
14 6.0 6.058 60.58 
15 6.7 6.760 67.60 
16 6.9 6.967 69.67 
17 7.2 7.269 72.69 
18 7.3 7.372 73.72 
19 7.9 7.973 79.73 
20 8.2 8.279 82.79 
21 8.4 8.482 84.82 
22 8.5 8.584 85.84 
23 8.9 8.985 89.85 
24 9.2 9.289 92.89 
 
Figure No: 17: IN VITRO DRUG RELEASE OF FORMULATION F10 
 
Slope = 3.320       r2 = 0.995 
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Fig: 18: SUMMARIZED IN VITRO DRUG RELEASES OF 
NANOPARTICLES 
FORMULATION (F1-F10) 
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7.5 MORPHOLOGY OF NANOPARTICLES: 
The characteristics of optimized nanoparticles formulation (F9) particle size 
were studied by simple microscopy. Small amount of sample was placed in glass slide 
and placed in simple microscope. Image of prepared nanoparticle formulation shows 
the encapsulation of polymer mixture on drug particles. 
 
 
 
 
 
Fig: 19:  MICROSCOPIC IMAGE OF NANOPARTICLES 
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7.6. SCANNING ELECTRON MICROCOPY
The surface characteristics of o
scanning electron microscopy. SEM image of prepared nan
shows the coating of po
nanoparticles in SEM is 400 nm
drug. 
Fig: 20
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7.7 SURFACE CHARGE (ZETA POTENTIAL)36 
  The zeta potential of a nanoparticle is commonly used to characterize the 
surface charges property of nanoparticles. It reflects the electrical potential of 
particles is influenced by the composition of the particles and the medium in which it 
is dispersed. When nanoparticle formulations are administered through intravenous 
route they are easily identified and detected by the phagocytes. The particle size and 
the hydrophobicity surface of the nanoparticle determine the adsorption of blood 
components (proteins) called as opsonins. This opsonin in turn decides the fate of the 
nanoparticles. Binding of these opsonins on to the surface is known as Opsonization. 
Non modified nanoparticles were rapidly opsonized and gets easily eliminated from 
the body. Hence, to increase the likelihood of the success in drug targeting by 
nanoparticles, it is necessary to minimize the opsonization and to prolong the 
circulation of nanoparticles in vivo. 
 The zeta potential of the nanoparticle formulation with Eudragit ( RS 100 & 
RL 100) (formulation F9) particles which present in the formulation are de-
aggregated and remain same  and more stable in the suspension and zeta potential 
(mV) is 59.0 and Zeta Deviation (mV) is 5.29 and conductivity (mS/cm ) is 0.0866. 
So this polymer is more suitable for nanoparticle preparation and the result shows 
smooth surface character and efficient repelled action and it decreases the 
opsonization.  
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7.8. STERILITY TEST73 
 The optimized Lamivudine loaded nanoparticle formulation (F9) was 
subjected to sterility test. The test was carried out as per specification Indian 
pharmacopeia. Both Soya bean casein digest medium (SCDM) and Fluid 
thioglycollate medium (FTM) were used. The method followed is Method A – 
Membrane filtration method. The positive control was prepared from standardized 
Bacillus subtilis suspension. The prepared nanoparticle samples dipped in SCDM and 
FTM incubated for 14 days. The result shows absence of turbidity. So it indicates the 
sterility of formulation passes the sterility test.   
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Fig: 21: Observation of Sterility test done in Soya bean Casein Digest medium 
(SCDM) 
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Fig: 22: Observations of sterility test done in Fluid Thioglycolate medium (FTM) 
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7.9 STABILITY STUDIES OF LAMIVUDINE NANOPARTICLES25,74 
  The stability studies of the optimized nanoparticle formulation F9 was 
carried out for 3 months. The test was performed in three condition 40C, room 
temperature and 450C/70%RH. At the time interval of one month the nanoparticle 
formulation were evaluated for entrapment efficiency. The stability of nanoparticle 
formulation was more stable in refrigerator (4°C) when compared to room 
temperature and at (450C/70%RH). 
 
Table.27: Stability studies of nanoparticles 
 
S.No 
 
Storage 
Condition 
 
Test 
parameters 
1st month 2nd month 3rd month 
 
1 
 
40C 
pH 
Colour 
 
Sterility 
7.5 
Clear& 
colour less 
Passes 
7.5 
Clear& 
colour less 
passes 
7.5 
Clear& 
colour less 
passes 
2 
Room 
temperature 
pH 
Colour 
 
Sterility 
7.4 
Clear& 
colour less 
Passes 
7.4 
Clear& 
colour less 
passes 
7.3 
Clear& 
colour less 
passes 
 
3 
Acceleration 
Conditions at 
45°C/70% 
RH 
pH 
Colour 
 
Sterility 
7.5 
Clear& 
colour less 
Passes 
7.3 
Clear& 
colour less 
passes 
7.3 
Clear& 
colour less 
passes 
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Table: 28: In vitro release for optimized formulation F9 stability study at 40C 
 
 
Time 
(Hrs) 
Cumulative % drug release 
 
1st month (%) 
 
2nd month (%) 
 
3rd month (%) 
1 8.0 12.0 7.0 
2 15.08 19.12 9.07 
3 19.18 21.19 13.09 
4 23.19 23.21 19.13 
5 26.23 24.23 24.19 
6 32.26 29.24 25.24 
7 38.32 31.29 32.24 
8 40.38 39.31 39.32 
9 40.40 41.39 48.39 
10 47.44 44.41 50.48 
11 52.47 48.44 54.50 
12 53.52 50.48 56.54 
13 58.53 52.50 60.56 
14 60.58 54.52 63.60 
15 67.60 57.54 65.63 
16 69.67 58.57 69.65 
17 72.69 64.58 72.69 
18 73.72 68.64 75.72 
19 79.73 69.68 77.75 
20 82.79 75.69 81.77 
21 84.82 79.75 82.81 
22 85.84 84.79 83.82 
23 89.85 86.84 87.83 
24 92.89 92.86 91.87 
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Fig: 21: STABILITY STUDY RELEASE DATA FOR FORMULATION F9 
AFTER THREE MONTHS AT 4°C 
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Table: 29: In vitro data for optimized formulation F9 stability study at room 
temperature 
 
Time 
(Hrs) 
Cumulative % drug release 
 
1st month 
 
2nd month 
 
3rd  month 
1 8.0 5.0 0.5 
2 10.08 7.05 07.05 
3 15.10 13.07 10.07 
4 16.15 17.13 15.10 
5 18.16 24.17 16.15 
6 23.18 29.24 18.16 
7 26.23 31.29 25.18 
8 28.26 34.31 28.25 
9 33.28 39.34 33.28 
10 35.33 45.39 34.33 
11 39.35 47.45 39.34 
12 40.39 49.47 41.39 
13 44.40 51.49 45.41 
14 46.44 53.51 47.45 
15 51.46 56.53 55.47 
16 55.51 61.56 57.55 
17 60.55 63.61 61.57 
18 66.60 68.63 66.61 
19 67.66 69.68 69.66 
20 69.67 71.69 72.69 
21 71.69 72.71 74.72 
22 72.71 77.72 76.74 
23 78.72 80.77 79.76 
24 83.78 82.80 81.97 
 
 
 RESULT AND DISCUSSION 
 
Dept. of Pharmaceutics, K.M. College of Pharmacy, Madurai 97 
 
 
 
 
Fig: 22: STABILITY STUDY RELEASE DATA FOR FORMULATION F9 
AFTER THREE MONTHS AT ROOM TEMPERATURE 
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Table: 30: In vitro data for optimized formulation F9 stability study at 
45°c/75%RH 
 
 
Time 
(Hrs) 
Cumulative % drug release 
 
1st month 
 
2nd month 
 
3rd  month 
1 6.0 2.0 4.0 
2 11.06 5.02 8.04 
3 13.11 7.05 10.08 
4 17.13 8.07 13.10 
5 21.17 13.08 14.13 
6 22.21 15.13 19.14 
7 26.22 19.15 25.19 
8 28.26 25.19 28.25 
9 30.28 26.25 30.28 
10 31.30 30.26 32.30 
11 34.31 31.30 35.32 
12 40.34 33.31 36.35 
13 42.40 36.33 40.36 
14 48.42 38.36 41.40 
15 51.48 42.38 43.41 
16 53.51 43.42 46.43 
17 57.53 45.43 48.45 
18 59.57 48.45 49.48 
19 61.59 51.48 54.49 
20 63.61 55.51 55.54 
21 67.63 60.55 61.55 
22 68.67 63.60 64.61 
23 73.68 65.63 66.64 
24 75.73 71.65 70.66 
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Fig: 23: STABILITY STUDY RELEASE DATA FOR FORMULATION F9 
AFTER THREE MONTHS AT 45°C /75% RH 
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Kinetics of drug release for optimized formulation F937 
The optimized formulation F9was introduced in to graphical treatment for 
kinetics of drug   release. 
 
 
Fig: 24: Zero order Plot for formulation F9 
 
Slope = 3.704 
Regression = 0.988 
 
The optimized formulation F9 of nanoparticle
.
is more suitable for parenteral 
administration it shows good in the in vitro release kinetic study. The zero order plots 
were obtained by plotting cumulative percentage drug release versus time. The 
regression value is 0.988. 
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HIGUCHI’S PLOT: 
 
 
  
 
Fig: 25: HIGUCHI’S PLOT FOR FORMULATION F9 
 
Slope = 20.93 
Regression = 0.973 
 
Higuchi plot was made by plotting cumulative % drug release against square 
root of time. The regression value was found to be 0.973. This indicates that diffusion 
is one of the mechanisms of drug release. 
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KORSEMEYER PLOT: 
 
 
 
Fig: 26: KORSEMEYER’S PLOT FOR FORMULATION F9 
 
n = 0.764 
 
The graph was plotted between log cumulative % of drug release and log time. 
The value was found to be 0.45 < n < 0.89 anomalous (non – fickian) diffusion. This 
indicates that the diffusion and erosion could be the reason for the mechanism of drug 
release. 
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8. SUMMARY AND CONCLUSION 
The present study Lamivudine nanoparticles aimed to develop a 
nanoparticulate drug delivery system of antiviral drug Lamivudine using 
biodegradable polymer Eudragit RS 100 & RL 100. 
The polymer enhances the binding of Lamivudine nanoparticles in specific or 
targeted site with sustained release of drug increasing therapeutic efficacy. These 
nanoparticles may also reduce the dose & dose frequency with desired therapeutic 
response. 
The pre-formulation studies were performed by using FTIR. The spectra of 
pure drug, pure polymer and nanoparticle formulation were examined. The study 
revealed the absence of significant interactions between drug and polymer. 
All batch of nanoparticles (F1-F10) were prepared by emulsion solvent 
evaporation method, formulation was subjected to evaluation involving following 
tests they are; 
 Entrapment efficiency. 
 In vitro drug release studies. 
 Microscopic determination. 
 Particle size determination 
 Sterility test. 
 Stability test. 
The entrapment efficiency of the optimized formulation was 94 ± 0.05%  and  
invitro drug release was 92.89% after 24 hours. It also obeys the zero order,follows 
diffusion and erosion mechanism of release. Particle size determination by Scanning 
Electron Microscope shows the best formulation containing size of about 100 nm.The 
formulation passed the sterility test performed as per specifications of Indian 
pharmacopoeia. The stability test performed revealed that the formulation was good. 
The best formulation was examined for zeta potential determinations. The formulation 
(F9) showed maximum deviation of -27mV which demonstrated that the particles are 
separate and highly repelling. This repelling property found to be more useful in 
decreasing opsonization and favors target specificity. The prepared formulation was 
sterilized by Membrane filtration technique. It was an aseptic technique involving the 
use of laminar air flow workstation. 
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